Detection and quantitation of synthetic cannabinoids in whole blood, urine and herbal products and its application to postmortem cases in Johannesburg, South Africa by Pon, Dale
  
Detection and quantitation of synthetic cannabinoids 
in whole blood, urine, and herbal products and its 
application to postmortem cases in Johannesburg, 
South Africa 
by 
Dale Pon 
A dissertation submitted to the Faculty of Health Science, University of the Witwatersrand, 
Johannesburg, in fulfillment of the requirements for the degree: 
MSc (Med) in Forensic Medicine 
Supervisors: 
aMs. Ildiko Jean Fenyvesi, bDr. Magda Rosemann & aDr. Guinevere Gordon   
 
aDepartment of Forensic Medicine and Pathology, School of Clinical Medicine, Faculty of 
Health Sciences, University of the Witwatersrand, Johannesburg, South Africa &                 
bThe Laboratory of The National Horseracing Authority of Southern Africa 
Johannesburg, 2016 
The financial assistance of the National Research Foundation (NRF) towards this research is hereby 
acknowledged. Opinions expressed and conclusions arrived at, are those of the author and are not, necessarily, 
to be attributed to the NRF.
ii 
 
Declaration 
I declare that this Dissertation is my own, unaided work.  It is being submitted for the degree 
of Master of Science in Medicine at the University of the Witwatersrand, Johannesburg.  It 
has not been submitted before for any degree or examination at any other university. 
 
____________________ 
(Signature of candidate)  
 
 
16th day of August 2016 
  
iii 
 
Presentations arising from this study 
Chrom SA 2015 Chromatography Postgraduate Student Seminar (oral presentation), 13 
August 2015, University of the Witwatersrand, Johannesburg. 
Faculty of Health Sciences - School of Clinical Medicine Research Day 2015 (poster 
presentation), 30 September 2015, University of the Witwatersrand, Johannesburg. 
SASBCP (South African Society for Basic and Clinical Pharmacology) & TOXSA (Toxicological 
Society of South Africa) Congress 2015 (poster presentation), 31 August – 2 September 2015, 
University of the Witwatersrand, Johannesburg.  
iv 
 
Abstract 
A study was conducted by J.W. Huffman in 1994, to design new compounds with effects 
comparable to natural cannabinoids, for example THC. This resulted in the synthesis of JWH-
018, which, along with C8 analogs of the cannabinoid CP 47,497 became the most common 
synthetic additives in several herbal blends known as ‘Spice’.  These herbal blends were 
originally sold online and in head shops (shops specialising in cannabis and tobacco 
paraphernalia) without age restriction or legal implications. In 2008 synthetic cannabinoids 
were identified in these mixtures and from early 2009, numerous countries began 
implementing legislation to monitor and control these drugs. 
The aim of this project was to develop and validate a LC-MS method for the detection and 
quantitation of several synthetic cannabinoids (JWH-018, JWH-019, JWH-073, JWH-081, 
JWH-122 JWH-200, JWH-250, AM-2201, (±)-CP 47,497, (C8)-CP 47,497, HU-211) and selected 
metabolites (JWH-018 N-(4-hydroxypentyl) metabolite and JWH-073 N-(3-hydroxybutyl) 
metabolite) in whole blood and urine. Further aims were to apply it to postmortem cases at 
the Johannesburg Forensic Pathology Services Medicolegal Laboratory (FPS-MLL) to assess 
the prevalence of these synthetic cannabinoids amongst the local postmortem population; 
as well as to known positive powder and urine samples obtained from a horseracing 
laboratory In Australia.  
Urine samples were extracted utilising an SPE method, while blood samples were extracted 
utilising an LLE method. LC-MS analysis was performed on a Thermo Fisher Q Exactive 
Orbitrap. Analytical parameters including: limit of detection (LOD), limit of quantitation 
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(LOQ), stability, matrix effects, selectivity, linearity, repeatability, accuracy, and recovery 
were assessed for each analyte.  
None of the postmortem cases were found to contain any of the targeted analytes, although 
validated methods for urine and whole blood were developed based on existing routine 
screening methods. The sample population could be extended to living subjects such as 
those in drug rehabilitation centres or in hospitals to get a more accurate representation of 
the overall usage in South Africa. 
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Chapter 1: Literature Review 
1.1. Cannabis - Introduction 
Cannabis (also known as Marijuana, and more informally as ‘weed’, ‘pot’, ‘grass’, or ‘herb’) 
has long been used as a drug of abuse due to its psychoactive effects. There is much debate 
and controversy surrounding the potential legalisation of cannabis, due to some of its 
therapeutic properties in the treatment of glaucomas, the stimulation of appetite in AIDS 
patients as well as the suppression of nausea resulting from chemotherapy (Adams and 
Martin, 1996). 
Cannabis (in the form of hemp) was used by the ancient Chinese and Greeks to make 
clothing and ropes, while the Romans used it in the construction of ships (Adams and 
Martin, 1996; Clarke and Merlin, 2013). It is also regarded as one of the oldest drugs in 
history where some research has indicated its use as far back as 2700 BC in China. It has also 
long been used as a medicine in a variety of countries, including China, India, the Middle 
East, South Africa and South America (Adams and Martin, 1996; Stafford, 2013). 
First isolated in 1964 (Gaoni and Mechoulam, 1964), tetrahydrocannabinol is the main active 
constituent of cannabis. Cannabis is used for a variety of purposes; as a recreational drug, in 
religious/spiritual rites or even for medicinal applications (Touw, 1981). Cannabis forms part 
of a group of compounds known as cannabinoids (produced by plants of Cannabis sativa and 
Cannabis indica). 
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Figure 1.1. Δ9-Tetrahydrocannabinol 
Cannabinoids are terpenophenolic compounds (i.e. a combination of a terpene, an 
unsaturated hydrocarbon group, C6H10; and a phenol, a benzene ring with a directly linked 
hydroxyl group, C6H5OH) which contain 21 carbons. There are three general types of 
cannabinoids; the phytocannabinoids (which occur in the cannabis plant), the endogenous 
cannabinoids (cannabinoids produced in the bodies of humans and animals), and synthetic 
cannabinoids (cannabinoids synthesised in a laboratory). In cannabis, the main active 
compound is the cannabinoid, Δ9-tetrahydrocannabinol (THC) (Figure 1.1.); although there 
are several others with known biological activity, such as cannabinol (CBN), cannabidiol 
(CBD) (which is thought to have analgesic and anti-inflammatory activity, without the 
psychoactive effect of THC), cannabichromene (CBC), cannabigerol (CBG), 
tetrahydrocannabivarin and Δ8-tetrahydrocannabinol (National Cancer Institute, 2014). 
1.2. Cannabinoid Receptors 
There are two kinds of cannabinoid receptors that have been found, named CB1 and CB2. 
Both of these receptors are G protein-coupled receptors, which are receptors that activate 
cellular responses by the activation of signal transduction pathways (Adams and Martin, 
1996; Devane et al., 1988). 
CB1 receptors are distributed predominantly throughout the brain and are found in high 
density in the basal ganglia, the cerebellar molecular layer, the innermost layers of the 
Page 3 of 88 
 
olfactory bulb, and parts of the hippocampal formation; while moderately distributed in the 
rest of the brain. Sparse amounts of CB1 receptors are also found in the brain stem and 
spinal cord (Glass et al., 1997; Herkenham et al., 1991). 
CB2 receptors have been found predominantly in immune tissues such as the spleen, tonsils, 
and thymus, as well as in some peripheral blood mononucleated cells (PBMCs) (Galiegue et 
al., 1995). In 1992 anandamide, the first naturally occurring substance within the brain which 
binds to CB1 receptors was discovered (Devane et al., 1992). Subsequently other naturally 
occurring substances which bind to CB1 receptors have been discovered and these 
substances, along with the receptors are known as the ‘endogenous cannabinoid system’. 
Cannabis tends to affect the limbic (the part of the brain that affects memory, cognition, and 
psychomotor performance) and mesolimbic (the part of the brain associated with feelings of 
reward) pathways as well as the areas of pain perception within the brain (Adams and 
Martin, 1996). This results in the commonly seen short-term effects of talkativeness; feeling 
of well-being; drowsiness; loss of inhibitions; decreased nausea; increased appetite; loss of 
coordination; bloodshot eyes; dryness of the eyes, mouth and throat as well as anxiety and 
paranoia. Furthermore, although research into the long-term effects of cannabis is limited, 
the most likely effects are increased risk of respiratory diseases associated with smoking, 
such as cancer; decreased memory and learning abilities; and decreased motivation towards 
studying, working and concentration (NCPIC (National Cannabis Prevention and Information 
Centre), 2008).  
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1.3. Synthetic Cannabinoids - Introduction 
Synthetic cannabinoids can be classified according to their chemical structure, into six 
groups: classical cannabinoids (THC, other constituents of cannabis as well as their 
structurally related synthetic analogues); nonclassical cannabinoids (i.e. cyclohexylphenols 
and 3-arylcyclohexanols); hybrid cannabinoids (have structural features of both classical and 
nonclassical cannabinoids); aminoalkylindoles (which consist of the subclasses 
naphtoylindoles, phenylacetylindoles, naphthylmethylindoles and benzoylindoles); 
eicosanoids (endocannabinoids such as anandamide and their synthetic analogues); and 
others (such as diarylpyrazoles, naphtoylpyrroles, naphthylmethylindenes or derivatives of 
naphthalene-1-yl-(4-pentyloxynaphthalen-1-yl)methanone) (Howlett et al., 2002). Examples 
of some of the classes can be seen in Figure 1.2. 
Research on synthetic cannabinoids has been on-going since the 1980s, with Pfizer 
developing CP 47,497 (Figure 1.3) (the “CP” indicating it is a cyclohexylphenol) as part of 
research to investigate which moieties of the molecule are the binding sites for analgesic 
activity. As a result it was discovered that CP 47,497 had an analgesic effect of similar 
potency to morphine (Melvin et al., 1984). 
Aminoalkylindoles, specifically pravadoline (WIN 48,098) and WIN 55,212-2 (Figure 1.3), 
were initially developed to be potential analogues of nonsteroidal anti-inflammatory drugs 
(NSAIDs), but were found to exhibit antinociceptive (pain inhibiting) properties. These 
properties were eventually explained by their interaction with the cannabinoid receptors, 
even though they have no structural relationship to traditional cannabinoids (Bell et al., 
1991; D’Ambra et al., 1992).  
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In an effort to design new indoles with effects comparable to natural cannabinoids such as 
THC, a study was conducted on cannabimimetic (which is defined by the United States 
Legislation in Section 1152 of the Synthetic Drug Abuse Prevention Act of 2012 as a 
“substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by 
binding studies and functional assays” (US Congress, 2012)) indole structures which resulted 
in the synthesis of several naphthoylindole compounds (which are aminoalkylindoles), most 
notably JWH-018, but also JWH-007, JWH-015, JWH-019, JWH-073, JWH-081, JWH-122, 
JWH-200, JWH-210, and JWH-398 (Huffman et al., 1994). 
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CP 47,497 CP 47,497 (C8) HU-211 
JWH-018 JWH-073 
JWH-122 JWH-250 
JWH-081 JWH-019 
JWH-200 AM-2201 
Figure 1.2. Chemical structures of several synthetic cannabinoids.  
Adapted from (United Nations Office on Drugs and Crime, 2011) 
a) Naphthoylindoles 
1) Aminoalkylindoles 
b) Phenylacetylindoles 
2) Cyclohexylphenols                                                                                3) Classical cannabinoids 
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1.4. Synthetic Cannabinoids - From the laboratory to the street 
JWH-018, along with C8 homologues of the non-classical cannabinoid CP 47,497 are the 
most common synthetic additives in a variety of herbal blends known as ‘Spice’ (Auwärter et 
al., 2009; Uchiyama et al., 2009). ‘Spice’ (and associated names such as K2, see Figure 1.4.) 
has been sold in numerous countries, including Switzerland, Austria, and Germany, since 
2004 and is marketed as incense, although it is smoked by users (Auwärter et al., 2009). Its 
popularity can be attributed to the fact that commonly used drug tests at the time were 
unable to detect these drugs in urine and blood as well as its ease of availability, from head 
shops (shops selling predominantly cannabis-smoking accessories) and the internet. 
Furthermore, ‘Spice’ is sold without age restriction by vendors. These products are sold for 
anywhere between 5 USD and 15 USD per gram (“Buy K2 incense,” 2016; Reed, 2010).  
  
(Onavi, 2006) 
Figure 1.3. Chemical  Structures of CP 47,497 (left), 
Pravadoline (WIN 48,098, middle), and WIN 55,212-2 (right) 
https://d14rmgtrwzf5a.cloudfront.net/sites/default/files/images/drugfactsspice2.jpg https://upload.wikimedia.org/wikipedia/commons/8 82/USMC-100201-M-3762C-001.jpg 
Figure 1.4. Examples of Spice (left) and K2 (right) 
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1.5. Synthetic Cannabinoids - Prevalence 
Research performed in the USA in 2012 (Johnston et al., 2012) found the prevalence of 
synthetic cannabinoids use to be 8.8% for 15-16 year olds and 11.3% for 17-18 year olds. An 
online study conducted by Mixmag and Guardian on over 15 500 people in 2011 (Global 
Drug Survey, 2012) found that 14.2% of the UK respondents had experimented with 
synthetic cannabinoids (3.3% in the previous 12 months) while 14% of US respondents had 
tried it in the previous 12 months. Two separate studies performed in Australia (Barratt et 
al., 2013; Scott et al., 2012) found that a significant number of synthetic cannabinoid users 
were also regular cannabis users (Barratt et al. (2013) found that 96% of the synthetic 
cannabinoid users were also cannabis users). 
Research undertaken in Japan on herbal samples acquired from the internet between June 
2008 and June 2009 (Uchiyama et al., 2010) found six different synthetic cannabinoids 
present spread among the samples, namely cannabicyclohexanol (CP 47,497 dimethyloctyl 
monologue; (C8)-CP 47,497), the trans-Diastereoisomer of (C8)-CP 47,497, CP 47,497, 
Oleamide, JWH-018, and JWH-073. A study conducted in Germany on blood serum samples 
from forensic psychiatric clinics, and rehabilitation clinics, in cases of criminal investigation 
as well as critical care units (in the cases of severe intoxication) between August 2011 and 
January 2012 (Kneisel and Auwärter, 2012) found 11 different synthetic cannabinoids out of 
a total of 30 that were tested for. Another study performed in Germany on blood serum 
samples from hospitals, detoxification and therapy centres, forensic psychiatric centres and 
institutes of forensic medicine (Dresen et al., 2011) tested for 10 different synthetic 
cannabinoids and found 5 present in 56.4% of the subjects. 
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Very few postmortem studies have been investigated but one conducted by Shanks et al. 
(2012b) on cases received  by their laboratory tested for the presence of JWH-018 and JWH-
073 in whole blood and found a 40% positivity rate, although their sample size was small (n = 
45). 
1.6. Synthetic Cannabinoids - Pharmacology 
The synthetic cannabinoids are usually administered by smoking since many of them are 
highly lipophilic and vaporise without decomposition under smoking conditions. This is 
thought to allow for the rapid onset of pharmacological effects. There have been some 
reports of oral consumption, but this is a less common manner of administration as the 
onset of any pharmacological action may be delayed due to initial first phase metabolism 
(United Nations Office on Drugs and Crime, 2011). 
The pharmacokinetics of the synthetic cannabinoids is only partially known, but the 
metabolism has been investigated by a variety of studies, both in vitro and in vivo. Most of 
the compounds are metabolised extensively by multiple phase 1 reactions, including 
monohydroxylation, dihydroxylation, oxidation of the hydroxylated metabolites, and N-
dealkylation (Hutter et al., 2012; Wintermeyer et al., 2010; Zhang et al., 2006). In urine, 
metabolites are found in the form of glucuronic acid conjugates (Sobolevsky et al., 2010). 
Research has also found that the synthetic cannabinoids JWH-018 and AM-2201 undergo 
cytochrome P450-mediated oxidation with CYP2C9 and CYP1A2 the major P450s involved 
(Chimalakonda et al., 2012). 
There have been numerous case reports which have documented the psychopathological 
and neuropsychiatric effects of certain synthetic cannabinoids. The effects included: blurred 
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vision, tremors, agitation, anxiety, hallucinations, nausea, vomiting, psychosis, paranoia, 
tachycardia, hypokalemia, and hypertension (Forrester et al., 2011; Hermanns-Clausen et al., 
2013a, 2013b; Papanti et al., 2013).  
1.7. Synthetic Cannabinoids - Legislation 
In 2008 synthetic cannabinoids were identified in the above studied herbal mixtures and 
subsequently, from early 2009 onwards, countries including Chile (“‘Chile prohibits use of 
drug ’Spice,” 2009); France (“‘Decree of February 24, 2009 amending the Decree of 22 
February 1990 establishing the list of substances classified as narcotics,’” 2009); Germany 
(“‘Narcotics Law : fashionable drug Spice is prohibited by Emergency Ordinance,’” 2009); 
Ireland (Kennedy, 2010); New Zealand (Ryan, 2014); Poland (“Report Health Committee of 
the Government’s draft law amending the law on preventing drug addiction (form No. 
1207).,” 2009); Romania (“GEO 6/2010 amending and supplementing Law no. 143/2000 on 
preventing and combating trafficking and illicit drug use and completing Law no. 339/2005 
on the legal regime of plants, narcotic and psychotropic substances and preparations.,” 
2010); Russia (“Resolution dated December 31, 2009 № 1186 On Amending Certain 
Resolutions of the Government of the Russian Federation on issues related to drug 
trafficking,” 2010); South Korea (“‘One days from the ’5- Meo - mipteu and psychotropic 
drugs designation",” 2009); and Turkey (“Decision Number : 2011/1310,” 2011) have 
legislation in place, which either classifies several of the compounds as “medicinal 
preparations”, “controlled substances” or outright illegal. Several US states have banned the 
sale of ‘Spice’ and related products, while in the UK a generic definition which includes 
structurally similar compounds and not just compounds present in herbal products has been 
developed (United Nations Office on Drugs and Crime, 2011). In December 2011, the Office 
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of National Drug Control Policy of the Executive Office of the President of the United States 
of America (Office of National Drug Control Policy of the Executive Office of the President, 
2011) published a “Fact Sheet” in which it recognised synthetic marijuana as a “rapidly 
emerging threat” as well as describing the efforts taken by various states to monitor and 
control it.  
1.8. Synthetic Cannabinoids - South Africa 
A News24 article from late 2011 (Pienaar, 2011) reports the availability of a legal synthetic 
drug in South Africa with “a similar effect on the body to that of dagga”. Upon further 
investigation the herbal blend was found to contain JWH-073, a synthetic cannabinoid. As 
mentioned previously, these drugs aren’t detectable by routine screening tests, and GC-MS 
(gas chromatography mass spectrometry) was required to detect it. Current legislation in 
South Africa (i.e. the South African Medicines and Medical Devices Regulatory Authority Act 
(No. 132 of 1998) (The South African Medicines and Medical Devices Regulatory Authority 
Act (No. 132 of 1998), 1998) as well as the Drugs and Drug Trafficking Act (No. 140 of 1992) 
(Drugs and Drug Trafficking Act (No. 140 of 1992), 1992)) means that cannabis (also known 
locally as dagga) and its plant derivatives are considered banned substances.  
A recent amendment (15 March 2012) to the Medicines and Related Substances Act, (No. 
101 of 1965) (Medicines and Related Substances Act (No. 101 of 1965), 1965) listed the 
following synthetic cannabinoids: JWH-018; JWH-073; JWH-200; CP 47,497; CP 47,497-C6; CP 
47,497-C7; CP 47,497-C8; CP 47,497-C9; and HU-210 as Schedule 7 substances, which is the 
highest pharmaceutical scheduled classification, meaning that these substances are to be 
strictly controlled and monitored. 
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A PubMed search including the terms ‘South Africa’, ‘synthetic cannabinoid’, and ‘Spice’ 
yielded no results, therefore due to the limited information one may conclude that such 
research has not been conducted or published in South Africa. However, a quick internet 
search for “spice k2 South Africa” yields several classifieds type sites on which several 
companies claim to sell Spice and K2 locally, although they tend to offer bulk quantities. 
1.9. Synthetic Cannabinoids Analysis – Literature Overview 
Tables A1 and A2 in the Appendix summarise extraction methods from literature for the 
analysis of synthetic cannabinoids in urine and whole blood respectively conducted by 
various research cohorts. 
Majority of the synthetic cannabinoid extraction methods make use of either liquid-liquid 
extraction (LLE) or solid-phase extraction (SPE). One group (Scheidweiler and Huestis, 2014) 
also utilised supported liquid extraction (SLE) (after an initial hydrolysis step) in which the 
same organic phases in LLE are used, but are coated onto an inert diatomaceous earth 
instead of being shaken together, to quantitate the synthetic cannabinoids in urine. 
In 2009 Auwärter et al. initially attempted to use routine qualitative analytical methods such 
as GC-MS, multi-target LC-MS/MS (liquid chromatography tandem mass spectrometry), and 
immunological screening methods to characterise ‘Spice’ products purchased from the 
internet. These methods did not reveal any evidence of illicit drugs or known active 
pharmaceutical ingredients due to no standards being available with comparable structures. 
Following this these products were subsequently characterised by thin layer 
chromatography (TLC), UV-vis spectroscopy, nuclear magnetic resonance (NMR) 
spectroscopy, and electron ionisation (EI)-MS (Auwärter et al., 2009). 
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Around a similar time Uchiyama et al. (2009) in Japan also analysed and characterised herbal 
products purchased off the internet, by means of LC-MS, GC-MS, high-resolution MS, and 
NMR. From this information they elucidated the structure of one of the unknown 
compounds and determined that it was the same as a cannabinoid (CP 47,497) previously 
synthesised by Pfizer (Melvin et al., 1984).  
Shortly afterwards (in 2012), a group of researchers at NMS Labs in the USA utilised TLC, GC-
MS, HPLC (high performance liquid chromatography), and LC-TOF-MS (liquid 
chromatography- time of flight mass spectrometry) to identify and quantitate several 
synthetic cannabinoids in herbal incense blends (Logan et al., 2012). 
After this initial period of identification and confirmation most researchers have developed 
and validated variants of LC-MS/MS methods to analyse synthetic cannabinoids in a variety 
of matrices. This has also been aided by synthetic cannabinoid standards becoming 
commercially available from companies such as LGC and Cerilliant. In 2010 a German group 
(Teske et al., 2010) developed an LC-MS/MS method to detect JWH-018 in blood serum. 
Following this, another German research group developed and validated LC-MS/MS methods 
to quantitate several synthetic cannabinoids in serum (Dresen et al., 2011; Kneisel and 
Auwärter, 2012), while an American research group developed and validated a similar 
method for the identification and quantitation of these drugs in whole blood (Kacinko et al., 
2011). Some researchers in Italy developed a matrix-assisted laser desorption ionisation- 
time of flight mass spectrometry (MALDI-TOF-MS) method for use with herbal blends, which 
they claim to be simpler, faster, and have a higher throughput than the usual GC-MS and LC-
MS methods (Gottardo et al., 2012). With the recent development of UPLC (ultra-
performance liquid chromatography), some methods have been developed for the analysis 
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of synthetic cannabinoids. One method made use of UPLC-TOF for the qualitative detection 
in non-biological specimens (Shanks et al., 2012a) while another utilised UPLC-MS/MS to 
determine concentrations as low as 0,01 ng/mL of two synthetic cannabinoids (JWH-018 and 
JWH-073) in whole blood (Shanks et al., 2012b). 
Similar approaches have been taken to analyse the metabolites of synthetic cannabinoids. 
De Jager et al. (2012) developed an LC-MS/MS method for the identification and 
quantitation of the urinary metabolites of eight JWH-type cannabinoids. Wohlfarth et al. 
(2013), developed a qualitative LC-MS/MS method (with a traditional hydrolysis step) to 
identify several metabolites of selected synthetic cannabinoids as well as their parent 
compounds in urine. Due to the lack of a comprehensive quantitative urinary method for 
synthetic cannabinoids Scheidweiler and Huestis (2014) developed and validated an LC-
MS/MS method for the quantitation (limit of detections (LOD) in the range of 0,1 – 0,5 
ng/mL) of 20 synthetic cannabinoids and 21 metabolites, as well as the semi-quantitation of 
12 additional metabolites in urine. 
All of these methods have been developed as specialised targeted methods, and it is not 
known whether these were incorporated into general screening methods or not.  
1.10. Conclusion 
Over the past few years the rapid rise in synthetic cannabinoids use and availability around 
the world has prompted various countries to put legislation in place in order to monitor and 
control these substances (United Nations Office on Drugs and Crime, 2011). In addition, 
South Africa has promulgated legislation scheduling some of the first generation synthetic 
cannabinoids as mentioned above. Unfortunately no data are available regarding the 
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prevalence of synthetic cannabinoid use in South Africa, nor is it known whether South 
African forensic laboratories can identify them. 
1.11. Aims and Objectives 
The aim of this project is to develop a liquid chromatography coupled with mass 
spectrometry (LC-MS) method for the detection and quantitation of synthetic cannabinoids 
in whole blood and urine; and to apply this method to investigate the prevalence of 
synthetic cannabinoids in unnatural deaths in Johannesburg, South Africa by analysis of 
whole blood and urine from postmortem cases. 
The objectives of this project are: 
 To develop and validate a LC-MS method for the detection and quantitation of 
several synthetic cannabinoids (JWH-018, JWH-019, JWH-073, JWH-081, JWH-122 
JWH-200, JWH-250, AM-2201, CP 47,497, (C8)-CP 47,497, HU-211) and selected 
metabolites (JWH-018 N-4OH pentyl metabolite and JWH-073 N-3OH butyl 
metabolite) in whole blood and urine. 
 To investigate the prevalence of synthetic cannabinoid use amongst victims 
autopsied at the Forensic Pathology Services Medico-legal Laboratory (FPS-MLL), 
Johannesburg, South Africa.  
 To determine the stability of the selected synthetic cannabinoids in whole blood and 
urine under normal storage conditions. 
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1.12. Expected Results 
Synthetic cannabinoids are quite a new addition to the drug market and as such it was 
expected to feature in a small percentage of the sample population alongside the common 
drugs of abuse such as cannabis and heroin. 
  
Page 17 of 88 
 
Chapter 2: Materials and Methodology 
This study was a prospective, cross-sectional, descriptive study. 
2.1. Materials 
Spice Cannabinoid Mix 1 consisting of JWH-200, JWH-250, (±)-CP 47,497, (C8)-CP 47,497, and 
HU-211 (100 µg/mL in ACN (acetonitrile)); Spice Cannabinoid Mix 2 consisting of JWH-019, 
JWH-081, JWH-122, and AM-2201 (100 µg /mL in ACN); THC (1 mg/mL in MeOH), 11-OH-THC 
(11-Hydroxy-Δ9-tetrahydrocannabinol) (100 µg/mL in MeOH), JWH-073 (100 µg/mL in ACN), 
JWH-018 N-(4-hydroxypentyl) metabolite (100 µg/mL in MeOH), and JWH-073 N-(3-
hydroxybutyl) metabolite (100 µg/mL in MeOH) solutions were purchased from Cerilliant, 
Sigma-Aldrich. JWH-018 (10 mg/mL in MeOH) and JWH-200 (10 mg/mL in ACN) solutions 
were purchased from Cayman Chemical. 1-Naphthalenyl (1-pentyl-1H-indol-3-yl)-
methanone-D11 (JWH-018-D11) (100 µg/mL in MeOH) and (1-Butyl-1H-indol-3-yl)-1-
naphthalenyl-methanone-D9 (JWH-073-D9) (100 µg/mL in MeOH) solutions were purchased 
from Chiron AS. Beta glucuronidase/arylsulphatase was purchased from Roche and di-
potassium hydrogen orthophosphate, sodium carbonate, sodium dihydrogen 
orthophosphate, and sodium hydroxide were purchased from Associated Chemical 
Enterprises, ACE. Acetonitrile and methanol were purchased from Honeywell Burdick and 
Jackson; 1-chlorobutane was purchased from Minema; ethanol was purchased from 
Radchem; dichloromethane, ethyl acetate, ethyl ether, hexane, and isopropanol were 
purchased from RCI Labscan; methyl tert-butyl ether was purchased from Riedel-de Haën; 
and 1-chlorobutane, acetic acid, formic acid, and sodium acetate were purchased from 
Sigma-Aldrich. X Select CSH: C18 5 µm, 2.1 x 150 mm column used was purchased from 
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Waters. Beckman TJ-6, Beckman JS-6, and Beckman Coulter Allegra X-12R centrifuges were 
used and double deionised water from a Siemens LaboStar evoqua water purifier was used 
for this research. 
2.1.1. Preparation of Calibrators and Quality Controls (QCs)  
A combined synthetic cannabinoids spiking solution was prepared in methanol containing 1 
µg/mL of each of the standards. The spiking solution was stored at -20°C. Calibrators and 
Quality Controls were prepared by spiking blank urine and whole blood from known drug-
free volunteers at the following concentrations: 
Urine:  
Calibrators: 0,0225 ng/mL, 0,225 ng/mL, 1,125 ng/mL, 2,25 ng/mL, 3,375 ng/mL, 4,5 ng/mL, 
and 6,75 ng/mL. 
QCs: High (4,5 ng/mL), Medium (1,125 ng/mL), and Low (0,1125 ng/mL). 
Blood:  
Calibrators: 0,0675 ng/mL, 0,675 ng/mL, 3,375 ng/mL, 6,75 ng/mL, 10,125 ng/mL, 13,5 
ng/mL, and 20,25 ng/mL. 
QCs: High (13,5 ng/mL), Medium (3,375 ng/mL), and Low (0,3375 ng/mL). 
A combined internal standard solution was prepared in methanol containing 1-Naphthalenyl 
(1-pentyl-1H-indol-3-yl)-methanone-D11 (JWH-018-D11) and (1-Butyl-1H-indol-3-yl)-1-
naphthalenyl-methanone-D9 (JWH-073-D9) at 30 ng/mL. 
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2.2. Sample Collection 
Samples were collected at the FPS-MLL Johannesburg situated at 25A Hospital Street, 
Braamfontein, 2001. Samples were obtained during routine medico-legal autopsies, where 
dissection and assessment of the body would already be required for the purposes of 
establishing with greater certainty the cause and circumstance of death as per the South 
African Inquests Act 58 of 1959, Section 2 i.e. “If the body of a person who has allegedly died 
from other than natural causes is available, it shall be examined by the district surgeon or 
any other medical practitioner, who may, if he deems it necessary for the purpose of 
ascertaining with greater certainty the cause of death, make or cause to be made an 
examination of any internal organ or any part or any of the contents of the body, or of any 
other substance or thing” (Inquests Act 58 of 1959, 1959) 
The population comprised all cases of unnatural deaths (fulfilling the below acceptance 
criteria) received at the FPS-MLL Johannesburg, which services the Johannesburg 
metropolitan area, over a five month period. The following areas fall under the jurisdiction 
of Johannesburg: Alexandra, Booysens, Bramley, Brixton, Cleveland, Diepsloot, Douglasdale, 
Fairlands, Hillbrow, Honeydew, Jeppe, JHB Central, Langlaagte, Linden, Midrand, 
Moffatview, Mondeor, Norwood, Parkview, Randburg, Rosebank, Sandringham, Sandton, 
Sophiatown, and Yeoville. 
Samples were analysed at the Laboratory of the National Horseracing Authority of Southern 
Africa situated at the Turffontein Racecourse. 
Inclusion criteria: 
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 All decedents between the ages of 14 and 60 years. 
 Decedents admitted to the FPS-MLL Johannesburg for medicolegal postmortem 
investigations.  
Exclusion criteria: 
 Cases which displayed signs of late decomposition, including putrefaction, 
adipocerous formation or mummification. 
 Cases of decedents who were extensively burnt. 
 Cases of decedents who had been previously hospitalised. 
 Cases of decedents younger than 14 years of age or older than 60 years of age. 
 Cases where autopsy was performed more than 72 hours after death as 
decomposition would already be present. 
Urine (approximately 5 – 10 mL) (n=85) was obtained, where available by puncturing the 
bladder using a syringe and needle. Blood (approximately 5 mL) (n = 126) was obtained using 
a syringe and needle from an incision made at the inner femoral region, and if this was 
unsuccessful, it was obtained from the upper subclavian region.  
Urine and whole blood samples were analysed as part of the validation batches described 
below. 
Small quantities of seized powders (n = 3) and positive urine samples (n = 4) were donated 
by Racing Analytical Services Limited, Victoria, Australia and couriered to South Africa where 
they were analysed. 
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Ethics clearance was obtained from the University of the Witwatersrand Human Research 
Ethics Committee (HREC), Clearance Certificate Number: M130428 (Figure A4 in the 
Appendix). 
2.3. Sample Storage 
Urine samples were collected and split between plastic tubes (no preservative) and 25 mL 
glass containers with screw tops. Blood samples were collected and split between plastic 
blood tubes containing EDTA (ethylenediaminetetraacetic acid) and 25 mL glass containers 
with screw tops. Samples were stored at -20°C until analysis. 
2.4. Extraction of Urine Samples 
The extraction procedure for the extraction of drugs of abuse from urine was identical to 
that used routinely by the Laboratory of the National Horseracing Authority of Southern 
Africa, as described below. 
3 mL of each urine sample, calibrator, and QC were transferred into separate 50 mL glass 
tubes, 3 mL of 2 M sodium acetate buffer (pH 5,5) and 20 µL of beta glucuronidase/ 
arylsulphatase solution was added to each sample. The samples were then hydrolysed 
overnight in a water bath at 37°C. This was followed by the addition of 160 µL of 5 M 
aqueous sodium hydroxide and 3 mL of 0,25 M phosphate buffer (pH 8) to keep a constant 
basic medium. After vortexing and leaving the samples to stand for 30 min to allow it to 
reach room temperature, 100 µL of internal standard was added and the samples were 
centrifuged for 20 minutes at approximately 3000 g. Samples were applied to C18 SPE 
cartridges conditioned with 2 mL MeOH followed by 2 mL double deionised water. The 
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columns were dried and eluted with 8 mL dichloromethane: ethanol (96:4), and the eluant 
dried under nitrogen gas at 40°C (5 - 10 psi), followed by reconstitution in 100 µL methanol, 
and submitted for LC-MS analysis. 
Application to Real Samples from Australia 
Small amounts (approximately 50 mg) of three different powders seized in Australia, 
confirmed to contain several synthetic cannabinoids and four positive workplace testing 
urine samples (different compounds than what was included in this study) from Australia 
were kindly donated by Paul Zahra of Racing Analytical Services Limited, Victoria, as positive 
control samples. The list of compounds included in the Australian method was also provided. 
The powders were diluted to an estimated concentration of 5 ng/mL in MeOH, and then split 
into 2 portions, of which one was hydrolysed. Both the diluted and the hydrolysed samples 
were then analysed. The urine samples were treated as described in Section 2.4 and 
analysed as described in Section 2.7. 
2.5. Extraction of Whole Blood Samples 
2.5.1. Adaptation of Urine Extraction Method 
An attempt was made to adapt the urine method described above for whole blood samples 
(without a hydrolysis step), which resulted in clogged SPE cartridges. A precipitation step 
was added in an attempt clean up the samples and remove proteins found in the blood. The 
SPE cartridges continued to get clogged due to the nature of the postmortem whole blood 
matrix, and subsequently this method was abandoned. 
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2.5.2. Evaluation of Sample Preparation Methods in Literature 
A pooled blood sample was spiked with standard synthetic cannabinoid mixture at 30 ng/mL 
and used to evaluate four different extraction methods from literature. 
A) LLE method developed by Kacinko et al., (2011): 
In a clean glass tube, 1 mL of sample, 1 mL of sodium carbonate buffer (pH 9,0), 50 µL 
internal standard, and 15 mL of hexane: ethyl acetate (99:1) was added. The tube was 
thoroughly mixed, and then centrifuged for 15 minutes at approximately 3000 g. The tube 
was frozen in a dry ice bath and the organic layer transferred to a clean glass tube. The 
organic layer was evaporated to dryness under nitrogen gas, using a Turbovap drier at 40°C, 
reconstituted in 100 µL methanol, and then submitted for LC-MS analysis. 
B) LLE method developed by Ammann et al., 2012.  
In a clean glass tube, 1 mL of sample, 2 mL of sodium carbonate buffer (pH 9,0), 50 µL 
internal standard, and 10 mL of 1-chlorobutane: isopropanol (90:10) was added. The tube 
was thoroughly mixed, and then centrifuged for 15 minutes at approximately 3000 g. The 
tube was frozen in a dry ice bath and the organic layer transferred to a clean glass tube. The 
organic layer was evaporated to dryness under nitrogen gas, using a Turbovap drier at 40°C, 
reconstituted in 100 µL methanol, and then submitted for LC-MS analysis. 
C)  LLE method developed by Shanks et al., 2012 (b). 
In a clean glass tube, 1 mL of sample, 2 mL of sodium carbonate buffer (pH 9,0), 50 µL 
internal standard, and 10 mL of ethyl ether was added. The tube was thoroughly mixed, and 
then centrifuged for 15 minutes at approximately 3000 g. The tube was frozen in a dry ice 
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bath and the organic layer transferred to a clean glass tube. The organic layer was 
evaporated to dryness under nitrogen gas, using a Turbovap drier at 40°C, reconstituted in 
100 µL methanol, and then submitted for LC-MS analysis. 
D) SPE method developed by Holm et al., 2013. 
In a clean glass tube, 1 mL of sample was added, along with 50 µL internal standard. To this, 
3 mL of acetonitrile: methanol (85:15) was added to precipitate the proteins. The tube was 
subsequently centrifuged for 15 minutes at approximately 3000 g, the organic layer 
transferred to a clean glass tube, and 4,5 mL 0,1 M acetic acid was added. This was added to 
a Strata-X Reversed Phase SPE cartridge which had been conditioned with 4 mL of 
acetonitrile: methanol (85:15) followed by 4 mL of 0,1 M acetic acid. Washing was 
performed with 3,5 mL of 0,1 M acetic acid followed by 3,5 mL of acetonitrile: 0,1 M acetic 
acid (70:30). The sample was eluted with two portions of 1.25 mL acetonitrile:  acetic acid 
(98:2). The eluate was further dried under vacuum for 5 minutes, evaporated to dryness 
under nitrogen gas (using a Turbovap drier at 40°C), reconstituted in 100 µL methanol, and 
then submitted for LC-MS analysis. 
The method by Ammann et al. (2012) was found to be the most suitable for sample 
preparation and was further evaluated before being used for all subsequent Whole Blood 
experiments, as can be seen in the Results chapter. 
2.6. Liquid Chromatography-Mass Spectrometry (LC-MS) Background 
For many years GC-MS was the gold standard for the systematic toxicological analysis of 
forensic samples, however the recent development of LC-MS from the early 1990s onwards 
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has enabled analysis of hydrophilic, thermolabile, and non-volatile analytes that weren’t 
covered by GC-MS in a satisfactory manner (Peters, 2011; Sergi and Napoletano, 2012). 
HPLC (the “LC” part of LC-MS) is a physical separation technique by which components of a 
mixture are separated based on their interactions with the mobile and stationary phases. In 
the current study reverse phase chromatography is being utilised which entails the use of a 
polar mobile phase (solvent) and a non-polar stationary phase (column). The above 
interaction of the components of the analyte with the mobile and stationary phase results in 
the various components being retained by the column for varying times (known as the 
retention time) depending on their polarity. In reverse phase chromatography non-polar 
components have higher retention times while polar compounds have lower retention times 
(Sirard, 2012). 
Mass spectrometry is an analytical technique which identifies and quantifies molecules 
based on the mass to charge (m/z) ratio of charged gas-phase ions. The sample is introduced 
(usually after having gone through a chromatographic method), and subsequently converted 
into charged gas phase ions by ionisation which are then transferred to the mass analyser. 
The ionisation technique used in this study was electrospray ionisation (ESI), a technique in 
which a high voltage is applied to the liquid sample to create the aerosol. ESI is considered a 
soft-ionisation technique as very little fragmentation occurs. Some of the advantages of 
using ESI are its wide range of polarity, its applicability to thermally labile compounds, as 
well as ionisation of compounds with high molecular weights (Dooley, 2015). 
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2.7. LC-MS Method 
The LC-MS settings used in this study were identical to those used routinely by the 
Laboratory of the National Horseracing Authority of Southern Africa where the laboratory 
work was conducted. This was done to assess how easily a new screening method could be 
integrated into already existing routine drug screening methods, so that the development of 
a completely new method would not be necessary.  
The LC-MS system consisted of a Thermo Fisher Q Exactive Orbitrap mass spectrometer 
fitted with a heated electrospray (HESI-II) and an Agilent 1260 Infinity HPLC system with a 
XSelect CSH C18 column (5 µm, 2,1 x 150 mm). Gradient elution was performed using 5 mM 
ammonium acetate in 0,1% formic acid, water: acetonitrile (98:2) (Solvent A) and 5 mM 
ammonium acetate in 0,1% formic acid, water: acetonitrile (2:98) (Solvent B). The gradient 
started with 98% Solvent A at a flow rate of 0,3 mL/min and decreased over 20 minutes to 
2% Solvent A, which was kept for 5 minutes. After this the flow rate was increased to 0,35 
mL/min for 3 minutes. Starting conditions were restored over 7 minutes to allow the system 
to re-equilibrate. The temperature was kept at 40°C and the pressure remained between 80 
and 150 psi. 
2.7.1. Data Processing 
Processing of data was done using Thermo Fisher ToxID (a sample of the generated report 
can be seen in Figure A3 in the Appendix). The ToxID software simply requires an Excel 
spread sheet comprising the compound name, elemental composition, polarity, and 
expected retention time; and it generates a PDF report with a trace of the extracted ions for 
each compound based on the accurate mass calculated from the monoisotopic mass to 
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charge ratio (m/z) (see Tables 3.1 and 3.4 for accurate masses and retention times of all the 
compounds). 
For the study of the various whole blood extraction techniques the intensities of the 
chromatogram peaks were monitored and compared. 
All processing was done with the allowable mass deviation set at 5 ppm (delta ppm = 
[(theoretical m/z – detected m/z)/theoretical m/z]) and retention time drift at 0,3 min. A 
signal to noise (S/N) ratio of ≥ 3 was required for confirmation. An explanation of the S/N 
ratio can be found below in 2.8.3. 
2.8. Method Validation Criteria 
Method validation was broadly based on the SANAS (South African National Accreditation 
System) TG 41-01 document (SANAS, 2008) which provides the recommended guidelines for 
both the verification and validation of forensic chemistry methods. These guidelines were 
used for the acceptance criteria. 
Parameters that were investigated include selectivity, linearity, limit of detection (LOD), limit 
of quantitation (LOQ), accuracy, precision, recovery, matrix effects, and stability. See Table 
A5 in the Appendix for the equations used. 
Seven calibrators (two replicates per batch) were prepared (in pooled negative urine and 
whole blood from volunteers) and analysed on four different days for urine and three 
different days for whole blood. Three QCs (three replicates) were included in each batch. 
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2.8.1. Selectivity 
Selectivity is the measure of the ability of the method to identify and quantitate the analytes 
in the presence of other substances, either endogenous or exogenous, in a sample matrix 
(Vessman et al., 2001).  
To assess the selectivity of the method the following criteria were used to process the data: 
retention time variance ≤ 0,3 minutes and accurate mass deviation ≤ 5 ppm was used to 
check for co-eluting or closely eluting compounds within the same accurate mass range. 
Blank samples from five individual non-drug users were also analysed with the first batch to 
check for co-eluting matrix peaks that could give rise to false positive results. 
2.8.2. Linearity 
The linearity of an analytical method is defined as its ability to produce results that are 
directly (or by mathematical transformations) proportional to the concentration of analytes 
in samples over a stipulated range (United Nations Office on Drugs and Crime, 2009). 
Linearity was assessed using calibrators over the range: 0,0225 ng/mL to 6,75 ng/mL for 
urine, and 0,0675 ng/mL to 20,25 ng/mL for whole blood. 
Deuterated 1-Naphthalenyl (1-pentyl-1H-indol-3-yl)-methanone-D11 (JWH-018-D11) and (1-
Butyl-1H-indol-3-yl)-1-naphthalenyl-methanone-D9 (JWH-073-D9) were used as internal 
standards to compensate for the loss of analyte during sample preparation. 
The criteria for acceptance for linearity were an R2 value ≥ 0,970 and a percentage difference 
of ≤ 25% for calibrators and QCs. In addition, no more than 2 points were excluded from 
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each set of standards. Failure to meet these criteria resulted in the validation being rejected 
for the specific compound. These criteria are based on those used by the Laboratory of the 
National Horseracing Authority of Southern Africa for substances below 50 ppb. 
2.8.3. Limit of Detection and Quantitation 
Limit of detection is defined as the smallest measured concentration from which it is 
possible to deduce the presence of an analyte with reasonable statistical certainty, and 
distinguish it from background noise. The minimum requirement is widely accepted to be an 
S/N ratio of 3. It is not regarded as a rugged or robust parameter as it is affected by minor 
changes in the analytical system (such as temperature, purity of reagents, matrix effects, and 
instrumental conditions) (United Nations Office on Drugs and Crime, 2009). 
Limit of quantitation is defined as the smallest measured concentration from which it is 
possible to quantitate the analyte with an acceptable level of accuracy and precision (United 
Nations Office on Drugs and Crime, 2009). The minimum requirement is widely accepted to 
be a signal to noise ratio of 10, so that the signal is certain to be the analyte and not 
background noise or unusual fluctuation (Armbruster et al., 1994). 
The aim of the project was not to determine the absolute LOD and LOQ for each compound. 
A calibration range was selected based on concentrations which would indicate recent use of 
synthetic cannabinoids prior to death. 
 The signal to noise ratio is illustrated in Figure 2.1 below. 
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The LOD was determined as the lowest calibrator which exhibited an S/N ratio of greater 
than 3, while the LOQ was determined to be the lowest calibrator which exhibited an S/N 
ratio of greater than 10. 
2.8.4. Accuracy and Precision 
Accuracy is the measure of the difference, due to systematic method and laboratory error, 
between the expectation of the test result and the accepted reference value, i.e. it is the 
degree of closeness of the determined value to the known ‘true’ value (Food and Drug 
Administration, 2013; United Nations Office on Drugs and Crime, 2009). 
Precision reflects the random errors which occur in the method by measuring the closeness 
of the analytical results obtained from a series of replicate measurements of the same 
measure under the stated conditions. There are two common sets of conditions by which 
precision is measured; repeatable and reproducible conditions. Repeatability conditions are 
those conditions which occur when an analyst analyses samples on the same day with the 
same instrument or materials in the same laboratory. Reproducible conditions are those that 
occur when one or several of the above is variable, e.g. different analysts, different days, 
http://www.sepscience.com/images/Fig1_HPLCSol124.jpg 
Figure 2.1. Illustration of Signal to Noise Ratio 
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different instruments, or different laboratories (United Nations Office on Drugs and Crime, 
2009). 
Accuracy and precision were calculated using the three replicate results for the High QC on 
four days for urine and three days for whole blood. Accuracy represented as the difference 
of the QC High and the theoretical value, and precision as the standard deviation (SD) and 
coefficient of variance (CV) of the replicates.  Acceptance criteria were values within ≤ 25% 
of the theoretical values, % RSD values ≤ 15%, and CV ≤ 10. 
2.8.5. Matrix Effects 
The matrix effect is defined as the interference (direct or indirect) of other substances in the 
sample on the response (Food and Drug Administration, 2013). 
The matrix effect was not fully investigated in this study. Urine and whole blood samples 
were taken from five drug-free volunteers at the Forensic Pathology Services Medicolegal 
Laboratory, Johannesburg and from the Laboratory of the National Horseracing Authority of 
Southern Africa, Turffontein as blank samples. All calibrators and QCs were prepared in 
pooled urine or whole blood, respectively, to eliminate any matrix effects. 
2.8.6. Stability 
Stability relates to the resistance of the substances to chemical changes such as 
decomposition or disintegration. One of the purposes of performing stability studies is to 
assess the extent to which the analytes are stable during the entire analytical procedure as 
well as during storage before and after analysis (United Nations Office on Drugs and Crime, 
2009). 
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In this study long term stability of urine and blood was assessed by storing spiked QCs for 3 
months at 4°C (the temperature of most refrigerators) and at -20°C (the temperature of 
most freezers). In addition freeze-thaw stability of the samples was also assessed (i.e. after 
being frozen for 3 months the samples were thawed and frozen 3 times on 3 consecutive 
days, then analysed). Only QC High results (4,5 ng/mL in urine, and 13.5 ng/mL in blood) 
were used to assess stability. 
For the statistical analyses means and standard deviations were determined.  
For sample collection and storage refer to 2.3 and 2.4 above. 
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Chapter 3: Results 
3.1. Urine Method Validation  
The LC-MS method for synthetic cannabinoids in urine was based on the existing validated 
routine method used by the Laboratory of the National Horseracing Authority of Southern 
Africa, as described under Sections 2.4 and 2.7. Only the additional synthetic cannabinoids 
were validated. A table containing a summary of the validation results can be found below 
(Table 3.1). 
Table 3.1: Urine Validation Results 
Drugs 
Ionisation 
Mode 
Retention 
time (min) 
Accurate 
mass (amu) 
R
2
 
Value 
No. of 
Calibrators 
Concentration 
Range (ng/mL) 
LOD 
(ng/mL) 
LOQ 
(ng/mL) 
JWH-018 Positive 19,47 342,18463 0,993 5 1,125 - 6,750 1,125 1,125 
JWH-019 Positive 20,12 356,20023 0,993 5 1,125 - 6,750 1,125 1,125 
JWH-073 Positive 18,69 328,16898 0,996 6 0,225 - 6,750 0,225 0,225 
JWH-081 Positive 19,75 372,19507 0,997 6 0,225 - 6,750 0,225 0,225 
JWH-122 Positive 20,23 356,20023 0,994 5 1,125 - 6,750 1,125 2,250 
JWH-200 Positive 12,61 385,19031 0,994 5 1,125 - 6,750 1,125 2,250 
JWH-250 Positive 18,45 336,19513 0,996 5 1,125 - 6,750 1,125 1,125 
AM-2201 Positive 17,83 360,1752 0,992 5 1,125 - 6,750 1,125 2,250 
(±)-CP 47,497 Negative 19,10 317,24854 * * * * * 
(C8)-CP 47,497 Negative 19,99 331,26425 * * * * * 
HU-211 Positive 20,33 387,28876 0,992 5 1,125 - 6,750 1,125 2,250 
THC Positive 20,97 315,23151 0,993 5 1,125 - 6,750 1,125 2,250 
11-OH-THC Positive 17,58 331,22623 0,991 3 3,375 - 6,750 3,375 3,375 
JWH-018 N-4OH 
pentyl metabolite 
Positive 15,41 358,17938 0,993 5 1,125 - 6,750 1,125 2,250 
JWH-073 N-3OH 
butyl metabolite 
Positive 15,24 344,16388 0,997 5 1,125 - 6,750 1,125 1,125 
* indicates results that did not meet the validation criteria. 
LOD = lowest calibrator which showed a S/N ratio ≥ 3. 
LOQ = lowest calibrator which showed a S/N ratio ≥ 10. 
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3.1.1. Selectivity 
No interfering compounds were found in the blank urine samples. All the extracted ion 
peaks fell within the retention time (0,3 min) and accurate mass (5 ppm) limits. 
3.1.2. Linearity 
All of the studied compounds except (±)-CP 47,497 and (C8)-CP 47,497, showed excellent 
linearity (R2 ≥ 0,991) as can be seen in Table 3.1. 
3.1.3. Limit of Detection and Quantitation 
Both the LODs and LOQs for the analytes in urine ranged from 0,225 ng/mL to 3,375 ng/mL 
(seen in Table 3.1).  
3.1.4. Accuracy and Precision 
A table summarising the accuracy and precision of the High QCs of the synthetic 
cannabinoids in urine can be seen below (Table 3.2) (the complete table can be found in the 
Appendix, Figure A8). 
The accuracy of the analytes ranged from 95 - 109% in urine. 
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Table 3.2: Summary of the Accuracy and Precision of the High QCs (4,5 ng/mL) of the 
Synthetic Cannabinoids in Urine 
 
* indicates results that did not meet the validation criteria. 
3.1.5. Stability 
Table 3.3 below shows the long-term stabilities of the studied compounds. 
 
 
 
 
Drugs No. of QCs 
Mean 
(ng/mL) 
Accuracy % SD % RSD CV 
JWH-018 7 4,688 104 0,456 9,519 0,095 
JWH-019 7 4,675 104 0,442 9,248 0,092 
JWH-073 7 4,788 106 0,333 6,883 0,069 
JWH-081 6 4,597 102 0,296 6,304 0,063 
JWH-122 7 4,791 106 0,444 9,156 0,092 
JWH-200 3 4,434 99 0,218 4,909 0,049 
JWH-250 5 4,415 98 0,241 5,478 0,055 
AM-2201 5 4,266 95 0,371 9,175 0,092 
(±)-CP 47,497 * * * * * * 
(C8)-CP 47,497 * * * * * * 
HU-211 8 4,885 109 0,241 5,066 0,051 
THC 8 4,573 102 0,365 7,873 0,079 
11-OH-THC 5 4,430 98 0,434 9,629 0,096 
JWH-018 N-4OH pentyl metabolite 5 4,610 102 0,408 8,933 0,089 
JWH-073 N-3OH butyl metabolite 5 4,327 96 0,488 11,858 0,119 
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Table 3.3: Long-term Stabilities (% Recovery) of the Synthetic Cannabinoids in Urine in 
Glass and Plastic Containers 
Drugs Medium 
Temperatures 
-20°C 4°C Freeze-Thaw 
JWH-018 Glass 78,71 ± 0,62 68,14 ± 7,71 78,71 ± 1,40 
  Plastic 67,56 ± 74,25 40,20 ± 19,21 49,81 ± 13,82 
JWH-019 Glass 67,64 ± 4,45 62,79 ± 9,48 73,35 ± 12,43 
  Plastic 46,09 ± 49,89 25,38 ± 12,15 30,87 ± 8,85 
JWH-073 Glass 75,90 ± 1,17 67,50 ± 5,57 78,38 ± 0,87 
  Plastic 71,33 ± 77,49 49,90 ± 16,25 58,82 ± 9,40 
JWH-081 Glass 57,56 ± 4,91 55,02 ± 3,93 66,69 ± 6,94 
  Plastic 38,53 ± 39,04 30,66 ± 4,12 36,43 ± 2,29 
JWH-122 Glass 72,00 ± 9,37 66,47 ± 5,88 90,09 ± 27,83 
  Plastic 49,66 ± 52,66 29,09 ± 15,27 37,30 ± 14,31 
JWH-200 Glass 75,01 ± 16,05 63,17 ± 20,54 75,12 ± 19,16 
  Plastic 82,57 ± 89,30 64,42 ± 6,19 73,74 ± 16,05 
JWH-250 Glass 79,04 ± 5,10 70,74 ± 3,45 69,50 ± 10,99 
  Plastic 84,99 ± 92,47 61,52 ± 15,26 67,48 ± 13,81 
AM-2201 Glass 85,80 ± 4,14 75,56 ± 4,21 73,23 ± 17,57 
  Plastic 81,86 ± 89,98 65,33 ± 6,13 66,23 ± 2,42 
(±)-CP 47,497 Glass 144,18 ± 7,32 91,95 ± 18,51 81,43 ± 39,25 
  Plastic 193,73 ± 212,33 141,45 ± 38,06 129,66 ± 37,01 
(C8)-CP 47,497 Glass 79,34 ± 38,74 57,52 ± 50,71 59,45 ± 50,17 
  Plastic 157,98 ± 174,72 108,00 ± 43,42 99,39 ± 29,65 
HU-211 Glass 118,35 ± 2,43 87,46 ± 10,41 117,80 ± 10,06 
  Plastic 127,55 ± 139,58 97,00 ± 26,85 97,73 ± 31,11 
THC Glass 117,66 ± 18,32 65,08 ± 12,48 140,64 ± 57,48 
  Plastic 155,00 ± 182,98 67,15 ± 32,73 88,86 ± 33,53 
11-OH-THC Glass 167,56 ± 19,22 100,17 ± 12,02 143,35 ± 42,18 
  Plastic 237,87 ± 272,42 164,49 ± 24,43 162,44 ± 8,06 
JWH-018 N-4OH  Glass 79,26 ± 12,04 77,36 ± 15,09 74,62 ± 20,94 
pentyl metabolite Plastic 99,04 ± 113,73 72,95 ± 6,28 75,20 ± 11,07 
JWH-073 N-3OH  Glass 90,22 ± 8,29 80,78 ± 4,26 73,29 ± 10,38 
butyl metabolite Plastic 103,27 ± 111,35 86,03 ± 4,44 89,20 ± 2,26 
n = 3 
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3.2. Blood Extraction Method 
A comparison of the peak intensities of the drugs in the four extraction methods described 
in 2.5.2) can be seen in Figure 3.1. As can be seen, the extractions based on Kacinko et al. 
(2011) and Holm et al. (2013) had intensities that were noticeably higher than the other two 
methods, although the method based on Ammann et al. (2012) also resulted in consistently 
high intensities. It was decided that the method based on Ammann et al. (2012) would be 
further investigated, as it could easily be integrated with an existing screening method. An 
attempt was made to improve the extraction efficiency by substituting the isopropanol 
component with ethyl acetate and methyl tert-butyl ether respectively (as these are 
commonly used solvents in forensics). A comparison of the results of the optimisation can be 
seen in Figure 3.2. The 1-chorobutane with 10% isopropanol showed unmatched intensities, 
between 3 and 5 times higher than the rest, and was used for the subsequent validation. 
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Figure 3.1. Graph showing the intensities of selected synthetic cannabinoids 
for the 4 extraction methods for whole blood investigated 
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3.3. Whole Blood Method Validation 
The method by Ammann et al. (2012) produced acceptable results for synthetic 
cannabinoids in whole blood, and due to compatibility with existing forensic methods was 
further validated. A table containing a summary of the validation results can be found below 
(Table 3.4).  
Additionally, due to initial analyst errors, the calibrators and quality controls were prepared 
at a much lower concentration than initially intended. As such, the QC Mediums and Lows 
were below the validated calibration range; and thus validation calculations were performed 
using only the QC High data. 
Table 3.4: Whole Blood Validation Results 
Drugs 
Ionisation 
Mode 
Retention 
time (min) 
Accurate 
mass (amu) 
R
2
 
Value 
No. of 
Calibrators 
Concentration 
Range (ng/mL) 
LOD 
(ng/mL) 
LOQ 
(ng/mL) 
JWH-018 Positive 19,38 342,18463 0,997 6 0,675 - 20,250 0,675 0,675 
JWH-019 Positive 20,02 356,20023 0,998 6 0,675 - 20,250 0,675 0,675 
JWH-073 Positive 18,61 328,16898 0,994 5 0,675 - 20,250 0,675 3,375 
JWH-081 Positive 19,65 372,19507 0,995 6 0,675 - 20,250 0,675 0,675 
JWH-122 Positive 20,13 356,20023 0,994 6 0,675 - 20,250 0,675 3,375 
JWH-200 Positive 12,65 385,19031 0,972 6 0,675 - 20,250 0,675 3,375 
JWH-250 Positive 18,37 336,19513 0,997 6 0,675 - 20,250 0,675 0,675 
AM-2201 Positive 17,75 360,1752 0,989 6 0,675 - 20,250 0,675 0,675 
(±)-CP 47,497 Negative 19,00 317,24854 * * * * * 
(C8)-CP 47,497 Negative 19,89 331,26425 * * * * * 
HU-211 Positive 20,25 387,28876 0,996 6 0,675 - 20,250 0,675 3,375 
THC Positive 20,86 315,23151 0,993 5 3,375 - 20,250 3,375 3,375 
11-OH-THC Positive 17,52 331,22623 0,995 5 3,375 - 20,250 3,375 3,375 
JWH-018 N-4OH 
pentyl metabolite 
Positive 15,36 358,17938 0,991 6 0,675 - 20,250 0,675 0,675 
JWH-073 N-3OH 
butyl metabolite 
Positive 15,17 344,16388 0,994 6 0,675 - 20,250 0,675 0,675 
* indicates results that did not meet the validation criteria. 
LOD = lowest calibrator which showed a S/N ratio ≥ 3. 
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LOQ = lowest calibrator which showed a S/N ratio ≥ 10. 
3.3.1. Selectivity 
No interfering compounds were found in the blank whole blood samples. All the excluded 
ion peaks fell within the retention time (0,3 min) and accurate mass (5 ppm) limits. 
3.3.2. Linearity 
All of the studied compounds except (±)-CP 47,497 and (C8)-CP 47,497, showed excellent 
linearity (R2 ≥ 0,970) and met the criteria for validation as can be seen in Table 3.4.  
3.3.3. Limit of Detection and Quantitation 
Both the LODs and the LOQs for the analytes in whole blood ranged between 0,675 ng/mL 
and 3,375 ng/mL (seen in Table 3.4).  
3.3.4. Accuracy and Precision 
A table summarising the accuracy and precision of the High QCs of the synthetic 
cannabinoids in whole blood can be seen below (Table 3.5) (the complete table can be found 
in the Appendix, Figure A9). The accuracy of the analytes ranged from 88 - 107% in whole 
blood.  
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Table 3.5: Summary of the Accuracy and Precision of the High QCs (13,5 ng/mL) of the 
Synthetic Cannabinoids in Whole Blood 
Drugs No. of QCs 
Mean 
(ng/mL) 
Accuracy % SD % RSD CV 
JWH-018 12 13,745 102 1,014 7,485 0,075 
JWH-019 11 13,846 103 1,369 10,020 0,100 
JWH-073 12 13,779 102 1,045 7,726 0,077 
JWH-081 11 14,467 107 1,367 9,621 0,096 
JWH-122 12 13,360 99 1,521 11,389 0,114 
JWH-200 11 12,733 94 1,109 8,663 0,087 
JWH-250 12 12,751 94 1,256 9,971 0,100 
AM-2201 11 11,865 88 1,219 9,851 0,099 
(±)-CP 47,497 * * * * * * 
(C8)-CP 47,497 * * * * * * 
HU-211 9 13,834 102 2,020 14,579 0,146 
THC 9 14,210 105 1,889 13,306 0,133 
11-OH-THC 8 13,682 101 1,645 12,197 0,122 
JWH-018 N-4OH pentyl metabolite 11 12,830 95 1,052 8,196 0,082 
JWH-073 N-3OH butyl metabolite 7 12,745 94 1,473 11,577 0,116 
* indicates results that did not meet the validation criteria. 
3.3.5. Stability 
The stability results are listed in Table 3.6.  
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Table 3.6: Long-term Stabilities (% Recovery) of the Synthetic Cannabinoids in Whole Blood 
in Glass and Plastic Containers 
Drugs Medium 
Temperature 
-20°C 4°C Freeze-Thaw 
JWH-018 Glass 34,98 ± 60,58 77,21 ± 3,62 82,69 ± 6,67 
 
Plastic 91,21 ± 2,29 98,97 ± 9,26 92,22 ± 9,14 
JWH-019 Glass 52,70 ± 45,79 51,18 ± 44,38 58,67 ± 50,91 
  Plastic 105,50 ± 6,66 * 72,26 ± 62,58 
JWH-073 Glass 79,41 ± 4,51 82,86 ± 2,24 58,96 ± 51,11 
  Plastic 91,72 ± 3,36 97,28 ± 3,08 90,40 ± 5,44 
JWH-081 Glass 24,19 ± 41,90 79,91 ± 5,07 55,14 ± 47,76 
  Plastic 97,57 ± 4,49 104,67 ± 11,53 98,78 ± 12,96 
JWH-122 Glass 49,89 ± 43,47 54,80 ± 47,79 55,31 ± 48,21 
  Plastic 88,22 ± 4,75 29,30 ± 50,75 99,00 ± 9,34 
JWH-200 Glass 63,96 ± 55,47 95,72 ± 5,87 65,19 ± 56,47 
  Plastic 115,20 ± 3,57 102,44 ± 13,28 114,81 ± 9,63 
JWH-250 Glass 58,46 ± 50,82 96,34 ± 6,65 64,59 ± 56,02 
  Plastic 106,40 ± 1,53 122,59 ± 9,84 108,75 ± 11,20 
AM-2201 Glass 25,43 ± 44,04 74,74 ± 4,57 51,61 ± 44,75 
  Plastic 51,46 ± 44,66 89,43 ± 4,07 75,85 ± 4,32 
(±)-CP 47,497 Glass * * * 
  Plastic * * * 
(C8)-CP 47,497 Glass * * * 
  Plastic * * * 
HU-211 Glass * * * 
  Plastic * * * 
THC Glass 65,11 ± 57,94 110,72 ± 7,76 82,15 ± 71,17 
  Plastic 80,28 ± 69,56 85,49 ± 4,79 38,69 ± 67,02 
11-OH-THC Glass * * * 
  Plastic * * * 
JWH-018 N-4OH  Glass 66,39 ± 59,79 98,61 ± 7,44 71,54 ± 61,98 
pentyl metabolite Plastic 117,24 ± 6,12 * 37,30 ± 64,61 
JWH-073 N-3OH  Glass 73,03 ± 65,77 71,98 ± 62,60 80,56 ± 70,06 
 butyl metabolite Plastic 39,00 ± 67,55 95,77 ± 12,28 40,44 ± 70,04 
* indicates results that did not meet the validation criteria. 
n = 3. 
3.4. Application to Postmortem Forensic Cases 
The postmortem forensic samples included 126 whole blood and 85 urine samples which 
were obtained over a 5 month period, from July 2014 to December 2014. 
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Shown below (Table 3.7) is a summary of the demographic information of the sample 
population. 
Table 3.7: Postmortem Cases Summary – Demographic Information 
GSW = Gunshot wound; MBA = Motorbike accident; MVA = Motorist vehicle accident; PVA = 
Pedestrian vehicle accident; others include burns electrocution, and gassing.  
None of the studied synthetic cannabinoids were detected in the studied population. 
3.5. Application to Real Samples from Australia 
These samples (both urine and powder) were analysed using the method described in this 
study and processed with the ToxID database provided by Paul Zahra of Racing Analytical 
Category Sub-category 
Urine % Distribution 
(n = 85) 
Blood % Distribution 
(n = 126) 
Age Group 15 - 24 15 15 
(years)  25 - 34 39 42 
  35 - 44 32 28 
  45 - 54 4 6 
  55+ 4 3 
  Unknown 7 6 
Racial affinity Black 85 83 
  White 11 11 
  Asian 1 2 
  Coloured 4 4 
Sex Male 92 86 
  Female 8 14 
Mode of Death Assault 2 2 
  Fall from Height 8 6 
  GSW 28 25 
  Hanging 7 13 
  MVA/MBA/Train 12 9 
  Overdose/Poisoning 2 2 
  Other 4 6 
  PVA 11 10 
  Stabbed 16 17 
  Strangulation/Suffocation 2 2 
  Unknown 7 10 
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Services Limited, which contained additional synthetic cannabinoids to the list validated in 
this study. 
Using the processing method provided, the method was able to detect the newer synthetic 
cannabinoids PB-22 and XLR-11 (neither were subjects of this study) in the powders (both 
the hydrolysed and diluted samples). Several other metabolites and traces of other synthetic 
cannabinoids were also found indicating that the purity of the powders is questionable. 
These results corresponded with the qualitative findings of Racing Analytical Services 
Limited, Victoria in Australia. 
In the urine samples several synthetic cannabinoids (JWH-018, UR-144, and XLR-11) and 
their urinary metabolites that had previously been confirmed were detected using the 
method developed. Once again several other synthetic cannabinoids and metabolites were 
also found in trace amounts, which were presumably impurities present in the substance 
consumed. 
The data for the analyses of the positive controls are not shown due to confidentiality 
reasons. 
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Chapter 4: Discussion 
This study aimed to assess how easily the newer synthetic cannabinoids could be integrated 
into existing screening methods. The method for urine specimens currently used by the 
Laboratory of the National Horseracing Authority of Southern Africa, and a whole blood 
method found in literature were found to be suitable for majority of the analytes. Both these 
methods are examples of commonly used methods with common solvents and techniques, 
allowing for their potentially easy implementation into local forensic laboratories.  
This method was validated for JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, 
JWH-250, AM-2201, HU-211, THC, 11-OH-THC, JWH-018 N-4OH pentyl metabolite, and JWH-
073 N-3OH butyl metabolite in urine and whole blood; based on selectivity, linearity, limit of 
detection (LOD), limit of quantitation (LOQ), accuracy, precision, matrix effects, and stability. 
The methods were not successfully validated for (±)-CP 47,497 and (C8)-CP 47,497 as several 
issues were encountered (such as ionisation efficiency and stability) that could be assessed 
in future work. Furthermore, future work on urine samples could include more metabolites, 
since this study focused mainly on the parent components and only two metabolites were 
analysed. 
4.1. Urine Method Validation 
4.1.1. Linearity 
Of the several studies undertaken on synthetic cannabinoids it appears only Scheidweiler 
and Huestis (2014) investigated CP 47,497-type compounds, and reported good linearity. In 
the current study, good recoveries were initially observed for (±)-CP 47,497 and (C8)-CP 
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47,497 in the first batch (102 and 94 %, respectively), but the concentration declined rapidly 
in subsequent batches to below detection limits. This indicates that these compounds might 
not be stable long term or that the storage conditions were not optimal. It is possible that 
this analytical method could be improved for compounds (±)-CP 47,497 and (C8)-CP 47,497, 
by preparing fresh spiking solution with each batch, as well as including an additional 
internal standard. This could have implications for forensics application as it may require a 
specific targeted method. 
4.1.2. Limit of Detection and Quantitation 
Both the LODs and the LOQs for the analytes in urine ranged from 0,225 ng/mL to 3,375 
ng/mL. Several of the compounds have a LOD which is the same as its LOQ. This is due to the 
lower calibrator not fulfilling the criteria of S/N ratio ≥ 3, while the calibrator above that had 
an S/N ratio ≥ 10 fulfilling both the LOD and LOQ criteria. In reality, the LOD lies somewhere 
between the lower and higher calibrator, however no additional calibrators were prepared 
in that range and the exact LOD is not quantifiable from this study. 
Scheidweiler and Huestis (2014) validated a similar LC-MS method for 20 synthetic 
cannabinoids and 21 metabolites in urine (10 of which were in common with this project) 
from 0,1 µg/mL to 100 µg/mL (100 ng/mL to 100000 ng/mL), which is significantly higher 
than the concentration range in this study. Wohlfarth et al. (2013) validated a method for 9 
synthetic cannabinoids and 20 metabolites (8 of which were in common with this project) in 
urine and determined their LODs in the range of 0,5 ng/mL to 10 ng/ mL, which is 
comparable to the LODs determined in this project (0,225 ng/mL – 3,375 ng/mL). 
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The highest calibrator for the urine validation was 6,750 ng/mL, which means that any values 
above this would fall outside the calibration range of this study. Thus a much larger error 
would be associated with them making the method semi-quantitative. 
4.1.3. Accuracy and Precision 
Due to the low concentration levels of the Low and Medium QCs (falling mostly outside the 
calibration range), the High QC (4,5 ng/mL) values were used for all accuracy and precision 
calculations. The accuracy of the analytes ranged from 95 - 109% in urine, with RSD values of 
between 4,9 and 11,9 % which are well within the acceptance criteria. 
De Jager et al. (2012) reported accuracy for their studied synthetic cannabinoid metabolites 
of 73,5 – 117,5 %, while Jang et al. (2013) reported 92 – 108% accuracy. Scheidweiler and 
Huestis (2014) achieved an accuracy of 86,5 – 118,3 % while another study in Portugal 
(Simões et al., 2014) reported accuracy of 90 - 115 %. This shows that the accuracy achieved 
in this study is of a comparable standard to international research, while having the 
advantage of screening for a large number of different compounds.  
4.1.4. Stability 
Storage of urine specimens in glass at -20°C is best for most of the compounds as they had 
higher recovery and lower standard deviations. For majority of the analytes storage in plastic 
resulted in lower recoveries and exceptionally high standard deviations. The very high 
recoveries (i.e. > 100) in several of the samples could be due to factors such as matrix 
enhancement, but more research would be needed.  Another possibility is that some of the 
compounds were not stable in the spiking solution. Initially, the stability samples were 
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prepared at the same time as the spiking solution. The spiking solution was stored frozen but 
was defrosted with each batch to prepare calibrators and QC samples. Thus, the stability 
samples might have had a higher concentration of drug than the QCs and calibrators. This 
might suggest a need to prepare a fresh spiking solution so as to eliminate stability issues. 
Caution should be exercised as a small sample size (only three replicates) was used and thus 
further research would need to be performed with more replicates to corroborate these 
results.  
Of the several studies undertaken on urine, very few have studied stability. Three groups 
didn’t study stability at all (de Jager et al., 2012; Grigoryev et al., 2011; Simões et al., 2014). 
Two groups (Scheidweiler and Huestis, 2014; Wohlfarth et al., 2013) only investigated 
stability over 3 days; while only one (Jang et al., 2013) investigated stability over 30 days 
(and reported good stabilities, 96 – 106 %, for JWH-018 and JWH-073 metabolites). 
4.2. Blood Extraction Method 
At first glance Figure 3.1 shows clearly that the method utilised by Holm et al. (2013) 
produced the highest intensities for many of the compounds, followed closely by that by 
Kacinko et al. (2011). When assessed closer however, the method employed by Holm et al. 
makes use of a polymer-based, strong cation mixed mode extraction column which is 
specific towards basic compounds (Phenomenex Inc., 2016). This is unsuitable for a general 
screening method which aims to test for a large number of compounds with varying 
polarities. The method by Ammann et al. (2012) was ultimately chosen as it yielded good 
intensities and requires solvents that are routinely used for forensic applications, thus 
making it easier to integrate with existing screening methods. In South Africa where many 
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facilities lack the proper equipment, a simple sample preparation method (such as this LLE 
method), is ideal.  
During optimisation of the Ammann et al. (2012) method it was observed that isopropanol 
resulted in the highest intensities. This significant difference can be attributed to the greater 
polarity as well as eluant strength of isopropanol (Reichardt, 2003). 
4.3. Whole Blood Method Validation 
4.3.1. Linearity 
The results suggest that the storage conditions of the spiking solution was not ideal for 
compounds (±)-CP 47,497 and (C8)-CP 47,497, as all the other compounds showed good 
linearity, but the compounds (±)-CP 47,497 and (C8)-CP 47,497 resulted in good linearity 
only on the first day and very poor linearity on subsequent days.  
Ammann et al. (2012) also reported several issues with (±)-CP 47,497 and (C8)-CP 47,497 as 
well citing possible matrix effects. These compounds require negative ionisation mode to be 
detected and showed a lower response possibly indicating a lower ionisation efficiency of 
the ESI source (Ammann et al., 2012). This implies that detecting these compounds is more 
challenging and may require a targeted method which isn’t ideal for forensic applications. 
4.3.2. Limit of Detection and Quantitation 
Both the LODs and the LOQs for the analytes in whole blood ranged from 0,675 ng/mL to 
3,375 ng/mL. Several of the compounds have a LOD which is the same as its LOQ. This is due 
to the lower calibrator not fulfilling the criteria of S/N ratio ≥ 3, while the calibrator above 
that had an S/N ratio ≥ 10 fulfilling both the LOD and LOQ criteria. In reality, the LOD lies 
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somewhere between the lower and higher calibrator however no additional calibrators were 
prepared in that range so the exact LOD is not quantifiable from this study. 
Kacinko et al. (2011) determined the LODs for JWH-018, JWH-019, JWH-073, and JWH-250 to 
be between 0,005 ng/mL and 0,020 ng/mL and the LOQ to be 0,1 ng /mL, while Holm et al. 
(2013) determined the LOD for 13 synthetic cannabinoids (4 of which were in common with 
this project) to be in the 0,1 ng/mL to 0,25 ng/mL range in whole blood. 
Also in whole blood, Shanks et al. (2012a) found the LOD for their studied synthetic 
cannabinoids (JWH-018 and JWH-073) to be 0,01 ng/mL with a linear range of 0,05 ng/mL to 
50 ng/mL.  
This study’s higher LODs and LOQs could be attributed to the method used that had already 
been optimised and validated for various other drugs of abuse. The intention of the method 
was not to optimise for the lowest LOD, but rather to be able to add compounds to an 
existing screening method. Furthermore, if one was only searching for synthetic 
cannabinoids the method and its analytical testing parameters could be optimised to achieve 
lower LODs and LOQs. In the forensic setting the LODs and LOQs from this study are 
sufficient as most decedents associated with substances of abuse have levels of the 
substance that is far greater than even the LOQs.  
The higher LODs and LOQs would be significant when attempting to detect trace amounts. A 
study conducted on postmortem cases to investigate synthetic cannabinoid use as a cause or 
contributory cause of death (Labay et al., 2016) included several cases where the levels of 
several of the synthetic cannabinoids were below the LOD of this study and would thus not 
be detected, which would be a significant limitation. Labay et al. (2016) studied 25 cases, 8 
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of which had a concentration of various synthetic cannabinoids below the LODs of this study, 
although 4 of them also contained additional synthetic cannabinoids which would have been 
detected. Synthetic cannabinoids were not reported as the cause of death in any of the case 
studies. They concluded that the role of synthetic cannabinoids in the cause and manner of 
death is still undefined as many of the cases involved alcohol as well as other drugs.  
The highest calibrator for the blood validation was 20,250 ng/mL, which means that any 
values above this would fall outside the calibration range of this study. Thus a much larger 
error would be associated with them making the method semi-quantitative. 
4.3.3. Accuracy and Precision 
Due to the low concentration levels of the Low and Medium QCs, the High QC (13,5 ng/mL) 
values were used for all accuracy and precision calculations. The accuracy of the analytes 
ranged from 88 - 107% in whole blood, with RSD values of between 7,5 and 15,0 % which are 
well within the acceptance criteria. This compares well with Kacinko et al. (2011) who 
reported accuracy (which translates to 91,8 to 108,2 %) for all their analytes except JWH-
019; Ammann et al. (2012) who reported that all their analytes fell within an acceptance 
interval of ± 15 % (i.e. 85 – 115 %); and Shanks et al. (2012b) who reported accuracy of 99,1 - 
107,0 % for JWH-018 and 97,7 – 102,0 % for JWH-073. 
4.3.4. Stability 
From Table 3.6 below it appears that not many of the analytes were stable over the three 
months in glass. A few of them, namely JWH-018, JWH-073, JWH-081, JWH-200, and JWH-
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250, appeared to be stable in plastic at all the temperatures as well as being freeze-thaw 
stable. 
Caution should be exercised when interpreting the data in Table 3.6 as a small sample size 
(only three replicates) was used and thus further research would need to be performed with 
more replicates to corroborate these results. Analytes for which no stability data was 
available at all include CP 47,497, (C8)-CP 47,497, HU-211, and 11-OH-THC. The very high 
recoveries (i.e. > 100) in several of the samples could be due to factors such as matrix 
enhancement, but more research would be needed.  
The stability of 11-OH-THC is not relevant as it is a metabolite of THC and will not ordinarily 
be found in blood. A previous stability study on THC (Christophersen, 1986) found that THC 
stored in plastic (polystyrene) containers suffered a significant loss (between 60 and 100%) 
after 4 weeks, while the amount of THC in glass containers remained unchanged. They 
theorised that it could be due to unknown compounds which diffuse from the plastic into 
the blood and form compounds which aren’t detected. 
Kacinko et al. (2011) analysed stability in plastic containers with several common 
preservatives and concluded that the collection container did not affect stability at room 
temperature, refrigerated (approximately 3° C) and frozen (approximately -10° C) up to 30 
days, however the stability of the compounds longer than that was not investigated. 
Amman et al. (2012) investigated long term stability, but only up to 42 days. They found all 
their studied compounds to be stable up to that point. 
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4.4. Application to Postmortem Forensic Cases 
From Table 3.7 it can be seen that the 25 to 34 year and 35 to 44 year age groups are the 
most prevalent in this sample, comprising 71% of the urine cases (n = 60) and 70% of the 
whole blood cases (n = 88), respectively. This is very similar to the National Injury Mortality 
Surveillance System (NIMSS) (NIMSS was a project started in 1999 to monitor and provide 
information about deaths due to external causes) 2009 report which listed the 20 to 29 year 
age group as having the highest number of mortality cases (Medical Research Council, 2009).  
Approximately 80% of victims were Black individuals and 11% were White individuals, which 
correlates directly with the findings of the 2011 Census for the Gauteng province (Statistics 
South Africa, 2012). 
The sex distribution of the study sample of males to females was at a ratio of 92:8 (n = 78 
and 7 respectively) for urine, and 86:14 (n = 108 and 18 respectively) for whole blood, which 
is a closer reflection of the NIMSS report (approximately 80:20) than of the Census results 
(approximately 50:50). 
None of the blood or urine samples tested positive for any of the studied synthetic 
cannabinoids; however several samples did test positive for common drugs of abuse 
included in the original screening method such as THC, benzodiazepines, 
methamphetamines, and opioids (data not shown).  
From an extensive literature search only one study has been conducted internationally on 
postmortem cases, and a literature search found no studies involving synthetic cannabinoids 
in South Africa. Shanks et al. (2012b) analysed 45 postmortem blood cases and found either 
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JWH-018, JWH-073, or both in 18 of the cases. Ammann et al. (2012) validated their method 
in both antemortem and postmortem blood samples but did not apply their method to 
actual samples. 
Analysing postmortem specimens provides numerous challenges since there are many 
factors that can influence the concentrations of substances of abuse in a decedent. Among 
these are postmortem interval (i.e. the time that has elapsed since a person has died), the 
condition of the body, as well as the little knowledge of many drugs’ in vivo stability and 
postmortem redistribution. In South Africa, bodies can be stored for several days in 
suboptimal storage conditions, where these factors play an even larger role.  
From the results obtained it is clear that the scope of research should be widened to include 
groups such as drug rehabilitation centres and seized drugs to obtain a more accurate 
representation of whether these drugs are being used in South Africa. If further research 
amongst these groups were to yield negative results then there is a good point to be made 
about these synthetic cannabinoids not being used in South Africa. If, however, positive 
results were found, the South African Police Services Forensics Science Laboratories would 
need to consider adding a screening test like the one presented in this study to their testing 
protocols. 
The use of LLE extraction is ideal for the South African environment as it is easy to perform, 
large numbers can be processed simultaneously, and it requires minimal equipment and 
apparatus (basic glassware is sufficient).  
As seen from several news articles (Serrao, 2014a, 2014b) the South African forensics labs 
are in an exceptionally bad state and thus there might even be cases with synthetic 
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cannabinoids, but by the time a postmortem investigation is conducted, a sample submitted, 
and then analysed, any trace amounts might have degraded already. 
4.5. Application to Real Samples from Australia 
The use of the method on real samples obtained from Australia serves to illustrate the 
versatility of using LC-HRAM-MS (liquid chromatography- high resolution accurate mass- 
mass spectrometry) for the detection of synthetic cannabinoids. In a field where the 
structures of drugs are constantly changing it is difficult to obtain and expensive to 
manufacture certified reference materials to keep up. LC-MS with accurate mass detection 
allows for the screening of forensic samples provided that the molecular formula of the 
compound is known or can be predicted. Only once these compounds are detected with a 
screening method will it be necessary to obtain the relevant reference materials for 
confirmation and quantitation. In this case, although a different LC-MS system was used, it 
was still possible to detect the compounds identified previously in the Australian laboratory 
by merely extracting the accurate mass of the compounds. 
4.6. Conclusion 
Overall majority of the studied cannabinoids exhibited excellent linearity (R2 ≥ 0,990), and 
good LODs and LOQs, 0,225 ng/mL and 3,375 ng/mL for urine, and 0,675 ng/mL and 3,375 
ng/mL for whole blood. Both THC and 11-OH-THC had higher LODs and LOQs in both 
matrices as their structures are significantly different from the synthetic cannabinoids and 
no internal standard was used for them. 
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The method could not be validated for two of the target compounds, (±)-CP 47,497 and (C8)-
CP 47,497. This is possibly due to stability of the compounds in the spiking solution used. 
These compounds ionise in negative mode in LC-MS, and due to limited resources an 
appropriate internal standard could not be acquired. Further optimisation of negative mode 
parameters may also improve the signal intensity and provide better results. 
The validation data indicated that the adaptation of existing routine screening methods to 
include several synthetic cannabinoids was mostly successful. This method provides a 
sensitive as well as selective way of screening for JWH-018, JWH-019, JWH-073, JWH-081, 
JWH-122, JWH-200, JWH-250, AM-2201, HU-211, THC, 11-OH-THC, JWH-018 N-4OH pentyl 
metabolite, and JWH-073 N-3OH butyl metabolite in urine and whole blood. 
Due to technical issues with the instrumentation some data were not obtained on Day 3 of 
the Whole Blood validation. The following compounds were affected: HU-211, THC, 11-OH-
THC, and JWH-018 N-4OH pentyl metabolite. 
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Chapter 5: Conclusion 
One of the main aims of this project was to adapt an existing laboratory method to include 
synthetic cannabinoids in the list of targeted analytes. 
Although adapting existing routine methods is quite straightforward one does not always 
obtain the sensitivity that can be achieved with specifically developed methods. This is 
because the objective of a forensic investigative analytical screen test is to be able to identify 
a wide variety of substances, which is not possible if you tweak a method for a narrow group 
of compounds. 
In the South African setting decedents are not routinely screened for drugs of abuse, only in 
cases with a history of abuse or when the pathologist suspects the involvement of drugs, will 
a specimen be collected for further testing. A further issue is the lack of information supplied 
with a decedent. 
This study has shown that it is possible to add any number of compounds to existing 
screening methods in a forensic environment and it is a viable strategy to test and screen for 
newer drugs of abuse such as synthetic cannabinoids (particularly the first generation 
variants studied). Adapting methods which are traditionally applied to antemortem cases 
were adapted and applied to postmortem samples with success. The only notable exceptions 
were the synthetic cannabinoids (±)-CP 47,497 and (C8)-CP 47,497 for which these methods 
were found to be unsuitable. For the other synthetic cannabinoids the method was 
successfully validated, for urine the LODs and LOQS ranged from 0,225 to 3,375 ng/mL; and 
for whole blood the LODs ranged from 0,675 to 3,375 ng/mL. 
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Whole blood is easier to obtain and almost always guaranteed in postmortem cases, 
whereas urine is a more difficult sample to obtain as victims may either empty their bladders 
prior to their death or the bladder could have been ruptured. Urine has the benefit of lower 
LODs and LOQs (since it’s a cleaner and simpler matrix), but there is the risk that many of the 
parent compounds of the synthetic cannabinoids might already have been metabolised. 
Internationally, the trend seems to be towards whole blood instead of urine, presumably for 
the aforementioned reasons. 
The data indicates that for urine samples should be stored in glass containers, while for 
blood, plastic containers with preservative were more suitable for long term storage. 
Furthermore, the lack of convincing stability data for many of the analytes suggests that any 
analysis of samples suspected to contain these compounds should be undertaken as soon as 
possible after sampling. 
One of the chief limitations of this research was that it only included postmortem cases, and 
was in a relatively concentrated, metropolitan area. 
Future prospects include widening the scope of research to include antemortem driving 
under the influence cases, rehabilitation centres, as well as drugs seized by the police. 
Furthermore, with greater resources the research could be extended to cover the whole of 
South Africa.  
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Appendix 
Table A1: Comparison of Extraction Methods in Literature for the Analysis of Synthetic Cannabinoids in Urine 
Authors 
Synthetic 
Cannabinoids 
Analysed 
Sample 
Volume (uL) 
Type of 
Extraction 
Solvent Buffer Notes 
Linear 
Range 
(ng/mL) 
(Rigdon et al., n.d.) 
JWH-018, 
JWH-073 
Metabolites: 
JWH-018, 
JWH-073 
 
SPE 
Preconditioning: ACN followed by 
Ammonium acetate in 0,1% acetic acid 
(pH 4,2).       
Washing: Ammonium acetate in 0,1% 
acetic acid.         
Elution: ACN followed by butyl 
chloride. 
Ammonium acetate,    
pH 5,0 
Hydrolysis with beta-
glucuronidase 
(ammonium acetate, pH 
5,0) performed. 
1 - 500 
(Grigoryev et al., 2011) 
JWH-018, 
JWH-073 
Metabolites: 
JWH-018, 
JWH-073 
LLE: 2500  
SPE: 3000 
LLE + SPE 
LLE: HCl, followed by chloroform. SPE: 
Preconditioning: H2O + ACN.       
Washing: 10 + 40% ACN in H2O.         
Elution: ACN followed by butyl 
chloride. 
  
N/A 
(de Jager et al., 2012) 
Metabolites: 
JWH-018, 
JWH-019, 
JWH-073, 
JWH-122,  
JWH-200, 
JWH-250, 
JWH-398, 
RCS-4 
500 LLE Diethyl ether. 
Ammonium acetate,    
pH 5.5 
Hydrolysis with beta-
glucuronidase (aryl 
sulfatase pH 5,5) 
performed. 
0,1 - 10 
(Hutter et al., 2012) 
Metabolites: 
JWH-018, 
JWH-073, 
JWH-081, 
JWH-122,  
1000 LLE t-butyl methyl ether 
Phosphate, pH 6; 
Borate, pH 9 
Hydrolysis with beta-
glucuronidase performed. 
N/A 
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JWH-210, 
JWH-250, 
RCS-4 
(Wohlfarth et al., 2013) 
JWH-018, 
JWH-073, 
JWH-081, 
JWH-122, 
JWH-210, 
JWH-250, 
RCS-4,      
AM-2201, 
MAM-2201 
Metabolites: 
JWH-018, 
JWH-073, 
JWH-081, 
JWH-122, 
JWH-200, 
JWH-210, 
JWH-250, 
RCS-4,      
AM-2201 
100 Precipitation 
 
Ammonium acetate,   
pH 4,0 
Hydrolysis with beta-
glucuronidase performed.   
Precipitation with ACN. 
0,5 - 10 
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(Scheidweiler and 
Huestis, 2014) 
JWH-018, 
JWH-019, 
JWH-073, 
JWH-081, 
JWH-122,  
JWH-200, 
JWH-203, 
JWH-210, 
JWH-250, 
JWH-398,    
CP 47,497-C7, 
CP 47,497-C8, 
HU-210,   
RCS-4,     
RCS-8,      
AM-694,    
AM-2201, 
MAM-2201, 
UR-144,   
XLR-11 
Metabolites:  
JWH-018, 
JWH-019, 
JWH-073, 
JWH-081, 
JWH-122,  
JWH-200, 
JWH-210, 
JWH-250, 
JWH-398, 
RCS-4,      
AM-2201, 
MAM-2201, 
UR-144,     
CP 47,497-C7, 
CP 47,497-C8 
SPE: 500 
SLE: 200 
SPE + SLE 
Preconditioning: ACN followed by 
Ammonium acetate (pH 4,0).      
Washing: H2O + ammonium acetate: 
ACN (80:20).         
Elution: 2% HAc (acetic acid) in ACN 
followed by hexane: ethyl acetate 
(90:10). 
Ammonium acetate,    
pH 4,0 
C8 and C18 SPE 
performed.      
Hydrolysis with beta-
glucuronidase performed 
0,05 - 
50 
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Table A2: Comparison of Extraction Methods in Literature for the Analysis of Synthetic Cannabinoids in Whole Blood 
Authors 
Synthetic 
Cannabinoids 
Analysed 
Sample 
Volume (uL) 
Type of 
Extraction 
Solvent Buffer Notes 
Linear 
Range 
(ng/mL) 
(Kacinko et al., 2011) 
JWH-018, 
JWH-019, 
JWH-073, 
JWH-250 
200 LLE Hexane: Ethyl acetate (99:1) Na2CO3, NaCl  
0,1 - 20 
(Ammann et al., 2012) 
AM-694, 
AM-1241,   
HU-210, 
WIN 48,498, 
WIN 55,212-2 
(mesylate), 
RCS-4, 
RCS-4-C-4 
homolog,   
RCS-4 3-me 
homolog,  
RCS-4 2-me 
homolog,  
RCS-8, 
CP 47,497, 
CP 47,497-C8 
homolog, 
JWH-007, 
JWH-015, 
JWH-018, 
JWH-019, 
JWH-030, 
JWH-073, 
JWH-081, 
JWH-203, 
JWH-210, 
JWH-250, 
100 LLE 1-Chlorobutane + 10% isopropanol 
Trizma, 
pH 9,2  
0,5 - 100 
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JWH-251, 
JWH-302, 
JWH-398 
(Shanks et al., 2012b) 
JWH-018, 
JWH-073 
500 LLE Ethyl ether Na2CO3,   pH 10,2  
0,05 - 50 
(Holm et al., 2013) 
AKB-48,    
AM-2201,  
HU-210,  
MAM-2201, 
UR-144, 
JWH-015, 
JWH-018, 
JWH-073, 
JWH-122, 
JWH-182, 
JWH-203, 
JWH-210, 
JWH-370 
200 SPE 
Preconditioning: 15% MeOH in ACN, 
followed by HAc. 
Washing: HAc, followed by HAc in ACN 
(70:30). Elution: 2% HAc in ACN. 
 
Initial protein 
precipitation step (15% 
MeOH in ACN used). 
0,25 - 10 
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Figure A3. Example of a ToxID Report 
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Figure A4. HREC Clearance Certificate 
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Table A5: Table of Statistical Equations 
Term Equation 
Correlation Coefficient (R) 
∑(       )
 
           
 ∑(       )
 
∑         
 
 
 
 
 
Regression Line        
Slope (m) 
∑(       )
 
           
∑(       )
  
Intercept (b)            
Residual Standard deviation 
(Standard error) 
  
 ⁄
   ∑
     ̂ 
 
   
 
 
 ⁄
 
Relative Standard deviation (RSD) 
  
 ̅ 
(100) 
Standard Deviation (s) √
∑       ̅̅ ̅ 
 
   
   
 
Mean 
∑  
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Table A6: Linearity of the Analytes in Urine 
Drugs   
Retention 
time(min) 
Slope (m) 
y-
Intercept 
R
2
 Value 
No. of 
Calibrators 
JWH-018 Day 1 19,50 0,3079 -0,006 0,999 7 
  Day 2 19,45 0,04095 0,029 0,980 5 
  Day 3 19,45 0,04925 -0,005 0,996 7 
  Day 4 19,48 0,04648 -0,001 0,998 7 
  Average 19,47 0,1112 0,004 0,993 6,5 
JWH-019 Day 1 20,15 0,2552 -0,025 0,996 7 
  Day 2 20,11 0,03463 0,009 0,990 5 
  Day 3 20,10 0,03868 -0,007 0,995 7 
  Day 4 20,12 0,03901 -0,010 0,991 5 
  Average 20,12 0,09188 -0,008 0,993 6 
JWH-073 Day 1 18,72 0,2249 0,006 0,999 7 
  Day 2 18,67 0,03865 0,002 0,996 7 
  Day 3 18,67 0,03844 -0,001 0,998 7 
  Day 4 18,70 0,04040 0,000 0,991 7 
  Average 18,69 0,0856 0,002 0,996 7 
JWH-081 Day 1 19,78 0,2467 -0,011 0,999 7 
  Day 2 19,72 * * * * 
  Day 3 19,73 0,03659 -0,003 0,998 7 
  Day 4 19,75 0,03466 -0,006 0,995 5 
  Average 19,75 0,1060 -0,007 0,997 6,33 
JWH-122 Day 1 20,26 0,2525 -0,017 0,999 7 
  Day 2 20,21 0,0352 0,008 0,991 7 
  Day 3 20,22 0,03696 -0,007 0,994 7 
  Day 4 20,24 0,03410 0,001 0,991 5 
  Average 20,23 0,08969 -0,004 0,994 6,5 
JWH-200 Day 1 12,59 0,1137 0,006 0,998 7 
  Day 2 12,58 0,01324 0,004 0,990 6 
  Day 3 12,61 0,01637 -0,003 0,996 6 
  Day 4 12,65 0,02958 0,006 0,990 5 
  Average 12,61 0,04322 0,003 0,994 6 
JWH-250 Day 1 18,45 0,5154 0,000 0,999 7 
  Day 2 18,44 0,07372 0,010 0,997 7 
  Day 3 18,44 0,07727 -0,004 0,998 6 
  Day 4 18,46 0,08696 0,018 0,989 5 
  Average 18,45 0,1883 0,006 0,996 6,25 
AM-2201 Day 1 17,86 0,2703 -0,008 0,999 7 
  Day 2 17,81 0,04129 0,013 0,991 6 
  Day 3 17,81 0,04845 -0,009 0,990 6 
  Day 4 17,84 0,04722 0,011 0,988 5 
  Average 17,83 0,10182 0,002 0,992 6 
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(±)-CP 47,497 Day 1 19,13 0,000113 0,000 0,992 6 
  Day 2 19,08 7,88E-06 0,000 0,973 4 
  Day 3 19,08 * * * * 
  Day 4 19,11 * * * * 
  Average 19,10 6,044E-05 0,000 0,983 5 
(C8)-CP 47,497 Day 1 20,03 0,0001243 0,000 0,994 6 
  Day 2 19,95 * * * * 
  Day 3 19,98 * * * * 
  Day 4 20,00 * *  * * 
  Average 19,99 0,0001243 0,000 0,994 5 
HU-211 Day 1 20,37 0,005749 0,000 0,992 7 
  Day 2 20,29 0,0005564 0,000 0,992 7 
  Day 3 20,32 0,0007053 0,000 0,990 7 
  Day 4 20,33 0,0006792 0,000 0,993 7 
  Average 20,33 0,001923 0,000 0,992 7 
THC Day 1 20,99 0,01757 0,000 0,996 7 
  Day 2 20,96 0,001515 0,001 0,999 7 
  Day 3 20,96 0,001912 -0,001 0,992 5 
  Day 4 20,98 0,001707 0,000 0,984 5 
  Average 20,97 0,005676 0,000 0,993 6 
11-OH-THC Day 1 17,61 0,009588 0,000 0,997 7 
  Day 2 17,58 0,001009 0,000 0,996 5 
  Day 3 17,55 0,001073 0,000 0,980 5 
  Day 4 17,58 * * * * 
  Average 17,58 0,003890 0,000 0,991 5,67 
JWH-018 N-4OH 
pentyl metabolite 
Day 1 15,45 0,2072 -0,001 0,999 7 
  Day 2 15,38 0,02638 0,004 0,995 6 
  Day 3 15,38 0,02948 -0,008 0,987 6 
  Day 4 15,42 0,04321 0,012 0,991 5 
  Average 15,41 0,07657 0,002 0,993 6 
JWH-073 N-3OH 
butyl metabolite 
Day 1 15,28 0,1582 0,007 0,999 7 
  Day 2 15,21 0,02446 0,000 0,999 6 
  Day 3 15,21 0,02563 -0,005 0,994 6 
  Day 4 15,25 * * * * 
  Average 15,24 0,06943 0,001 0,997 6,33 
* indicates results that did not meet the validation criteria. 
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Table A7: Linearity of the Analytes in Whole Blood 
Drugs 
 
Retention 
time(min) 
Slope (m) 
y-
Intercept 
R
2
 Value 
No. of 
Calibrators 
JWH-018 Day 1 19,38 0,05167 -0,023 0,998 6 
  Day 2 19,37 0,04667 -0,007 0,999 6 
  Day 3 19,37 0,04475 -0,019 0,992 7 
  Day 4 19,38 0,05127 -0,025 0,999 6 
  Average 19,38 0,04859 -0,019 0,997 6,25 
JWH-019 Day 1 20,02 0,03684 -0,019 0,998 6 
  Day 2 20,00 0,03521 -0,008 0,999 6 
  Day 3 20,02 * * * * 
  Day 4 20,02 0,03685 -0,020 0,998 6 
  Average 20,02 0,0363 -0,016 0,998 6 
JWH-073 Day 1 18,61 0,08901 -0,029 1,000 6 
  Day 2 18,59 0,03598 0,038 0,983 6 
  Day 3 18,61 0,001907 -0,002 0,994 5 
  Day 4 18,61 0,04364 -0,015 0,999 6 
  Average 18,61 0,04263 -0,002 0,994 5,75 
JWH-081 Day 1 19,66 0,04886 -0,016 0,998 6 
  Day 2 19,64 * * * * 
  Day 3 19,64 0,0005064 0,000 0,990 6 
  Day 4 19,66 0,04752 -0,014 0,998 6 
  Average 19,65 0,0323 -0,010 0,995 6 
JWH-122 Day 1 20,14 0,0345 -0,021 0,998 6 
  Day 2 20,13 0,03147 -0,004 0,998 6 
  Day 3 20,11 0,0002501 0,000 0,982 5 
  Day 4 20,14 0,03448 -0,022 0,998 6 
  Average 20,13 0,02518 -0,012 0,994 5,75 
JWH-200 Day 1 12,49 0,06159 -0,068 0,973 6 
  Day 2 12,76 * * * * 
  Day 3 12,86 * * * * 
  Day 4 12,49 0,05864 -0,063 0,971 6 
  Average 12,65 0,06012 -0,066 0,972 6 
JWH-250 Day 1 18,37 0,09275 -0,033 0,997 6 
  Day 2 18,35 0,09478 -0,045 0,998 5 
  Day 3 18,37 0,000637 -0,001 0,994 6 
  Day 4 18,37 0,09111 -0,032 0,997 6 
  Average 18,37 0,06982 -0,028 0,997 5,75 
AM-2201 Day 1 17,75 0,06537 -0,031 0,995 6 
  Day 2 17,74 0,05619 0,010 0,986 6 
  Day 3 17,74 0,001718 -0,005 0,982 5 
  Day 4 17,75 0,06366 -0,028 0,994 6 
  Average 17,75 0,04674 -0,014 0,989 6 
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(±)-CP 47,497 Day 1 19,01 6,945E-05 0,000 0,988 6 
  Day 2 18,99 0,0001203 0,000 0,997 5 
  Day 3 * * * * * 
  Day 4 19,01 6,545E-05 0,000 0,989 6 
  Average 19,00 8,507E-05 0,000 0,991 5,67 
(C8)-CP 47,497 Day 1 19,90 * * * * 
  Day 2 19,88 * * * * 
  Day 3 * * * * * 
  Day 4 19,90 * * * * 
  Average 19,89 * * * * 
HU-211 Day 1 20,25 0,0005673 0,000 0,995 6 
  Day 2 20,24 0,0006534 -0,001 0,997 5 
  Day 3 * * * * * 
  Day 4 20,25 0,0005635 0,000 0,997 6 
  Average 20,25 0,0005947 0,000 0,996 5,67 
THC Day 1 20,87 0,001917 -0,001 0,999 6 
  Day 2 20,84 0,001672 -0,002 0,989 5 
  Day 3  * * * * * 
  Day 4 20,87 0,001931 -0,001 0,999 6 
  Average 20,86 0,00184 -0,001 0,996 5,67 
11-OH-THC Day 1 17,53 0,001846 -0,001 0,991 6 
  Day 2 17,50 0,001196 0,000 0,997 6 
  Day 3 * * * * * 
  Day 4 17,53 0,001679 0,000 0,996 6 
  Average 17,52 0,001574 0,000 0,995 6 
JWH-018 N-4OH 
pentyl 
metabolite 
Day 1 15,36 0,06125 -0,028 0,991 6 
  Day 2 15,34 0,04054 0,014 0,992 5 
  Day 3 15,37 * * * * 
  Day 4 15,36 0,06055 -0,028 0,989 6 
  Average 15,36 0,05411 -0,014 0,991 5,67 
JWH-073 N-3OH 
butyl 
metabolite 
Day 1 15,18 0,04218 -0,014 0,998 6 
  Day 2 15,17 0,03036 0,023 0,992 6 
  Day 3 15,16 0,0004981 -0,001 0,989 6 
  Day 4 15,17 0,04091 -0,012 0,998 6 
  Average 15,17 0,02849 -0,001 0,994 6 
* indicates results that did not meet the validation criteria. 
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Table A8: Accuracy and Precision of the High QCs of the Analytes in Urine 
Drugs   
Mean 
(ng/mL) 
Accuracy % SD % RSD CV 
JWH-018 Day 1 4,517 100 0,088 1,953 0,020 
  Day 2 5,045 112 0,769 15,237 0,152 
  Day 3 4,504 100 0,512 11,366 0,114 
  Average 4,688 104 0,456 9,519 0,095 
JWH-019 Day 1 4,375 97 0,137 3,120 0,031 
  Day 2 4,919 109 0,659 13,398 0,134 
  Day 3 4,731 105 0,531 11,226 0,112 
  Average 4,675 104 0,442 9,248 0,092 
JWH-073 Day 1 4,924 109 0,361 7,324 0,073 
  Day 2 4,840 108 0,530 10,957 0,110 
  Day 3 4,601 102 0,109 2,367 0,024 
  Average 4,788 106 0,333 6,883 0,069 
JWH-081 Day 1 4,377 97 0,155 3,533 0,035 
  Day 2 * * * * * 
  Day 3 4,816 107 0,437 9,074 0,091 
  Average 4,597 102 0,296 6,304 0,063 
JWH-122 Day 1 4,573 102 0,164 3,579 0,036 
  Day 2 4,998 111 0,553 11,064 0,111 
  Day 3 4,803 107 0,616 12,824 0,128 
  Average 4,791 106 0,444 9,156 0,092 
JWH-200 Day 1 4,434 99 0,218 4,909 0,049 
  Day 2 * * * * * 
  Day 3 * * * * * 
  Average 4,434 99 0,218 4,909 0,049 
JWH-250 Day 1 4,380 97 0,318 7,253 0,073 
  Day 2 * * * * * 
  Day 3 4,451 99 0,165 3,702 0,037 
  Average 4,415 98 0,241 5,478 0,055 
AM-2201 Day 1 4,537 101 0,071 1,555 0,016 
  Day 2 * * * * * 
  Day 3 3,996 89 0,671 16,795 0,168 
  Average 4,266 95 0,371 9,175 0,092 
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* indicates results that did not meet the validation criteria.  
(±)-CP 47,497 Day 1 4,577 101,711 0,563 12,311 0,123 
  Day 2 * * * * * 
  Day 3 * * * * * 
  Average * * * * * 
(C8)-CP 47,497 Day 1 4,227 93,941 0.065 1,526 0,015 
  Day 2 * * * * * 
  Day 3 * * * * * 
  Average * * * * * 
HU-211 Day 1 4,663 104 0,434 9,318 0,093 
  Day 2 5,405 120 0,129 2,379 0,024 
  Day 3 4,587 102 0,161 3,500 0,035 
  Average 4,885 109 0,241 5,066 0,051 
THC Day 1 4,347 97 0,229 5,272 0,053 
  Day 2 4,527 101 0,348 7,679 0,077 
  Day 3 4,845 108 0,517 10,670 0,107 
  Average 4,573 102 0,365 7,873 0,079 
11-OH-THC Day 1 4,582 102 0,673 14,698 0,147 
  Day 2 * * * * * 
  Day 3 4,279 95 0,195 4,561 0,046 
  Average 4,430 98 0,434 9,629 0,096 
JWH-018 N-4OH 
pentyl metabolite 
Day 1 4,714 105 0,241 5,109 0,051 
  Day 2 * * * * * 
  Day 3 4,507 100 0,575 12,757 0,128 
  Average 4,610 102 0,408 8,933 0,089 
JWH-073 N-3OH 
butyl metabolite 
Day 1 4,783 106 0,302 6,305 0,063 
  Day 2 * * * * * 
  Day 3 3,871 86 0,674 17,410 0,174 
  Average 4,327 96 0,488 11,858 0,119 
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Table A9: Accuracy and Precision of the High QCs of the Analytes in Whole Blood 
Drugs 
 
Mean 
(ng/mL) 
Accuracy % SD % RSD CV 
JWH-018 Day 1 14,045 104 1,570 11,180 0,112 
 
Day 2 14,386 107 0,654 4,549 0,045 
 
Day 3 14,236 105 0,598 4,204 0,042 
 
Day 4 12,315 91 1,232 10,007 0,100 
 
Average 13,745 102 1,014 7,485 0,075 
JWH-019 Day 1 13,369 99 1,889 14,132 0,141 
 
Day 2 14,083 104 0,650 4,613 0,046 
 
Day 3 14,561 108 1,010 6,940 0,069 
 
Day 4 13,374 99 1,925 14,394 0,144 
 
Average 13,846 103 1,369 10,020 0,100 
JWH-073 Day 1 13,547 100 1,586 11,707 0,117 
 
Day 2 14,772 109 0,530 3,588 0,036 
 
Day 3 13,876 103 0,667 4,810 0,048 
 
Day 4 12,922 96 1,395 10,798 0,108 
 
Average 13,779 102 1,045 7,726 0,077 
JWH-081 Day 1 13,889 103 1,064 7,661 0,077 
 
Day 2 13,916 103 2,691 19,339 0,193 
 
Day 3 16,096 119 0,812 5,042 0,050 
 
Day 4 13,967 103 0,899 6,440 0,064 
 
Average 14,467 107 1,367 9,621 0,096 
JWH-122 Day 1 13,397 99 1,363 10,175 0,102 
 
Day 2 13,263 98 1,487 11,214 0,112 
 
Day 3 13,293 98 1,888 14,201 0,142 
 
Day 4 13,487 100 1,344 9,966 0,100 
 
Average 13,360 99 1,521 11,389 0,114 
JWH-200 Day 1 12,273 91 1,388 11,306 0,113 
 
Day 2 12,287 91 0,317 2,584 0,026 
 
Day 3 13,709 102 1,335 9,737 0,097 
 
Day 4 12,664 94 1,396 11,025 0,110 
 
Average 12,733 94 1,109 8,663 0,087 
JWH-250 Day 1 12,549 93 1,727 13,759 0,138 
 
Day 2 12,053 89 0,913 7,577 0,076 
 
Day 3 13,719 102 0,425 3,099 0,031 
 
Day 4 12,684 94 1,960 15,450 0,154 
 
Average 12,751 94 1,256 9,971 0,100 
AM-2201 Day 1 11,861 88 1,511 12,742 0,127 
 
Day 2 13,283 98 1,738 13,081 0,131 
 
Day 3 10,151 75 0,129 1,268 0,013 
 
Day 4 12,163 90 1,498 12,314 0,123 
 
Average 11,865 88 1,219 9,851 0,099 
(±)-CP 47,497 Day 1 * * * * * 
 
Day 2 * * * * * 
 
Day 3 21,898 162 3,104 14,174 0,142 
 
Day 4 14,807 110 1,526 10,306 0,103 
 
Average 18,353 136 2,315 12,240 0,123 
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(C8)-CP 47,497 Day 1 12,983 96 0,720 5,543 0,055 
 
Day 2 20,138 149 2,612 12,971 0,130 
 
Day 3 * * * * * 
 
Day 4 12,644 94 0,536 4,238 0,042 
 
Average 16,561 123 1,666 9,257 0,093 
HU-211 Day 1 13,963 103 2,205 15,789 0,158 
 
Day 2 13,491 100 1,719 12,741 0,127 
 
Day 3 * * * * * 
 
Day 4 14,047 104 2,136 15,207 0,152 
 
Average 13,834 102 2,020 14,579 0,146 
THC Day 1 14,158 105 2,314 16,346 0,163 
 
Day 2 14,266 106 1,072 7,516 0,075 
 
Day 3 * * * * * 
 
Day 4 14,207 105 2,281 16,055 0,161 
 
Average 14,210 105 1,889 13,306 0,133 
11-OH-THC Day 1 13,184 98 1,931 14,647 0,146 
 
Day 2 14,512 107 0,918 6,325 0,063 
 
Day 3 * * * * * 
 
Day 4 13,349 99 2,085 15,618 0,156 
 
Average 13,682 101 1,645 12,197 0,122 
JWH-018 N-4OH 
pentyl metabolite 
Day 1 12,759 95 1,590 12,463 0,125 
 
Day 2 13,470 100 0,624 4,630 0,046 
 
Day 3 12,224 91 0,471 3,851 0,039 
 
Day 4 12,866 95 1,523 11,840 0,118 
 
Average 12,830 95 1,052 8,196 0,082 
JWH-073 N-3OH 
butyl metabolite 
Day 1 12,550 93 1,667 13,281 0,133 
 
Day 2 * * * * * 
 
Day 3 12,885 95 0,877 6,804 0,068 
 
Day 4 12,802 95 1,875 14,648 0,146 
 
Average 12,745 94 1,473 11,577 0,116 
* indicates results that did not meet the validation criteria. 
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Figure A10. Turnitin Originality Report 
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